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Abstract 
Human Papillomaviruses (HPV) contribute significantly to the global cancer burden, 
causing nearly all cervical cancers and varying proportions of head and neck, and other 
anogenital cancers. Previous studies, limited to small sample sizes or single tissue sites in 
studies, have suggested that HPV+ tumours can exhibit distinct molecular profiles.  
Initially, a comprehensive transcriptional signature was established for HPV-driven 
tumourigenesis and culminated in the confirmation of a driver role for HPV outside the 
Oropharynx in Head and Neck cancer and the discovery of prognostically relevant 
differences in the immune microenvironment with implications for patient 
management. Analysis of exomes for mutagenesis by APOBEC3B, found upregulated in 
HPV+ tumours, identified it as a key driver of genomic evolution in these tumours, and 
broadly as a determinant of hotspot specificity in PIK3CA mutations across cancers.  
Establishment of HPV-associated DNA methylation signatures, useful for classification, 
also highlighted novel HPV-related transcriptional changes and putative heterogeneity in 
cell-of-origin associated with HPV types and tissue sites. Analyses of transcriptional and 
epigenetic heterogeneity in Cervical Cancer, where multiple HPV types are causal, 
identified HPV45-associated molecular signatures indicative of increased invasiveness 
and inflammation with putative applications in patient stratification. Finally, Support 
Vector Regression approaches developed to perform deep deconvolution of the cellular 
composition of tumours facilitated integrative analysis of immune cell infiltration 
patterns, the prognostic patterns discovered in the thesis and molecular variation, 
offering insights into the role of the immune microenvironment in shaping the evolution 
of these tumours.   
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Chapter 1: Introduction  
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1.1 Human Papillomaviruses: An introduction 
Papillomaviruses are a distinct family of evolutionarily ancient dsDNA (double stranded 
DNA) viruses with 189 types known in 2010 which infect a wide range of mammalian, 
avian and reptilian hosts, most often causing hyperproliferative structures called 
papillomas when they manifest visibly, while also causing latent infections and 
microscopic lesions which may be underestimated due to sampling biases (Bernard, Burk 
et al. 2010). Human papillomaviruses show a tropism for infections of epithelial tissues 
and often contribute to a phenotype of hyperproliferation (Orlando, Brown et al. 2013). 
A subset of these viruses, designated as high risk types, are capable of driving malignant 
transformation of infected cells and account for nearly all cases of cervical cancer 
(Schiffman, Castle et al. 2007). Some high-risk HPV subtypes are also responsible for 
driving an epidemic of head and neck squamous cell carcinomas (HNSC) (Marur, D'Souza 
et al. 2010). Currently, the World Health Organisation defines 12 distinct HPV types as 
high-risk types with sufficient evidence for a causal role in cervical cancer (CESC: Cervical 
Squamous Cell Carcinoma and Endocervical Adenocarcinoma) , with 6 additional types 
putative candidates with limited evidence for carcinogenicity in humans (Bouvard, Baan 
et al. 2009).  
1.2 Classification and properties of human papillomaviruses. 
More than a 100 different human papillomavirus types have been identified to date. 
Those with an affinity for mucosal surfaces are classified under alpha-papillomaviruses 
while those with a propensity to infect cutaneous tumours are classified under beta-
papillomaviruses.  
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Figure 1: A Phylogeny of Human Papillomaviruses based on L1/L2 homology. Sourced from 
the IARC monograph on HPV. Types implicated in carcinogenesis by the WHO are labelled 
in orange (Bouvard, Baan et al. 2014).  
 
Some of the alpha-papillomaviruses are associated with the development and 
progression of mucosal cancers and they mainly fall into "species" (In this thesis, I refer 
to them as Clades) Alpha-7 and Alpha-9. These types have been highlighted in orange in 
(Figure 1) and comprise "high-risk" types, the carcinogenic potential of which enjoys 
strong evidential support according to the WHO (Bouvard, Baan et al. 2014).  
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The distribution of HPV types amongst oral and anogenital tissues and cancers is subject 
to high levels of variability, with the exception of HPV16, which is the largest contributor 
to the burden of HPV-driven cancers on a pan-tissue basis (Saraiya, Unger et al. 2015).  
1.3 The genome structure of Human Papillomaviruses: a synopsis.  
Human papillomaviruses are dsDNA viruses with genome sizes of around 8kb. The basic 
organisation of the genome features two late proteins that encode the capsid (L1 and 
L2), a Long Control Region (LCR) and a total of eight early proteins that perform a wide 
range of functions (Zheng and Baker 2006) (Figure 2). 
 
 
Figure 2: Genome structure of HPV16 and functions of the various proteins encoded in the 
genome. From (Stanley 2012) 
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Particularly important to HPV driven carcinogenesis are the E6 and E7 early proteins, 
which are described in detail in a subsequent section, and these are produced from a 
bicistronic RNA containing both E6 and E7. The production of E7 from this transcript 
requires splicing to yield a truncated E6 isoform called E6*whereas the retention of an 
intron is required to yield full length E6, meaning that the production of fully functional 
E7 can only happen at the expense of fully functional E6 (Tang, Tao et al. 2006).   
1.4 The Burden of HPV-induced cancers 
The burden of HPV driven cancers is the heaviest in the developing world, where access 
to screening may be limited, and close to 80% of CESC occurs there (Marur, D'Souza et 
al. 2010) with associated mortality of close to 50% (Ferlay, Soerjomataram et al. 2014). 
Protective vaccination is now available and has so far been demonstrated to be 
efficacious and capable of establishing an immune response (Paavonen, Naud et al. 
2009) but is only optimally effective pre-exposure and decreased costs are an essential 
step towards global immunisation (Baussano, Lazzarato et al. 2013). A bivalent and a 
quadrivalent anti-HPV vaccine have been traditionally employed, primarily targeting, 
amongst hrHPV, HPV18 and HPV16 with demonstrated cross-protection against other 
related types, albeit one that wanes with time (Malagon, Drolet et al. 2012) and a 
nonavalent vaccine targeting 9 HPV types has been recently introduced (Handler, 
Handler et al. 2015). 
1.5 Cancers are defined by a distinct set of hallmarks.  
Cancer is a broad set of diseases defined by collection of common, characteristic 
features, often referred to as the Hallmarks of Cancer (Hanahan and Weinberg 2000).  
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 Some of these features, including accelerated proliferation, resistance to growth-
suppressive signals, evasion of apoptosis (programmed cell death), the ability to be self-
sufficient in pro-proliferative signalling, creating an inflammatory microenvironment, 
establishing a nutritional supply through angiogenesis, replicative immortality and most 
importantly, to break through the basement membranes of the tissues they initially 
form in to then establish colonies at distant sites (metastasis) were well known in the 
last decade (Hanahan and Weinberg 2000).  Other hallmarks such as rewiring the normal 
biochemistry of metabolism and evolving to evade the immune system have emerged 
more recently (Hanahan and Weinberg 2011). 
1.6 Cancer is a disease of genes and genomes.  
The hallmarks of cancer mentioned in the previous paragraph evolve by disruption of 
genome structure and function. These can involve DNA sequence changes, either by 
mutation or large structural changes that modulate how many copies of genes exist 
within cells. These changes can contribute to changes in the sequence, and therefore 
structures, of proteins encoded by these genes, thus rewiring cell signalling, or change 
how much of the protein is produced. Alterations in signalling networks are coupled to 
gene expression programs that are also known to be dysregulated in cancers. Genes 
dysregulated in cancer with a tangible effect on tumour fitness may either be proto-
oncogenes (tumour promoting when activated) or tumour suppressors (anti-tumour 
activity unless disrupted). There are also genomic events that do not contribute to 
changes in fitness of cells that carry them in a population, which are referred to as 
passenger events.  
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Genes can also be dysregulated in cancer through epigenetic means (not involving 
sequence changes in the DNA of those genes) but are described separately in a later 
section.  
1.7 Cell cycle checkpoints  
The cell cycle refers to the set of all events that transpire between successive rounds of 
cell division. There are four distinct phases of a typical cycle of mitotic division, G1, S, G2 
and M and a G0 phase where cells are not dividing. Protein signalling cascades at the 
transition between the G1-S checkpoint and the G2-M checkpoint are involved in 
regulating if a cell proceeds through the cell cycle to complete division, experience cell 
cycle arrest due to a wide variety of cellular and environmental conditions, or 
permanently exit the cell cycle. The G1-S checkpoint marks a transition between 
progression dependent on an external mitogenic signal to signal-independent 
progression (Vermeulen, Van Bockstaele et al. 2003).  
1.8 High-risk HPV E6 and E7 dysregulate the cell cycle and generate the initial hits 
needed for malignant transformation.  
The genomes of high-risk HPV strains encode multiple proteins, of which E6 and E7 are 
the most critical for carcinogenesis. E6 recruits the E6AP protein to form a virus specific 
ubiquitin ligase that targets the tumour suppressor TP53 for degradation (Kao et al, 
2000). E7 binds to the retinoblastoma protein Rb and deregulates the R point transition 
from mitogen dependent to mitogen independent growth of the cell cycle in infected 
keratinocytes.   
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Rb, depending on phosphorylation levels, is capable of sequestering the E2F family of 
transcription factors, which activates a large subset of genes required to progress 
through to the S phase of the cell cycle. E7 is capable of directly binding to Rb via an 
LXCXE amino acid sequence motif and allows HPV transformed cells to bypass this cell 
cycle checkpoint (Harbour and Dean 2000). A key event in the development of HPV 
positive tumours is the integration of the HPV genome into host cells (Pett and Coleman 
2007), which facilitates the loss of inhibition by the E2 protein (Collins, Constandinou-
Williams et al. 2009). The E2 protein has been shown to prevent the expression of 
integrated HPV genomes by sequestering Brd4, a chromatin reader that recruits a 
transcriptional elongation factor to stimulate gene expression (Yan, Li et al. 2010) in 
addition to repression by direct binding to promoter elements that govern the 
expression of the viral early genes (Dowhanick, McBride et al. 1995).  However, episomal 
maintenance in the cellular background of a lack of detectable integrants has been 
reported with HPV16 in in W12 transformed keratinocytes (Gray, Pett et al. 2010), and 
confirmed  later in cancers, suggesting cells can still be locked into an E6/E7 expressing 
state without integration (Tang, Alaei-Mahabadi et al. 2013), even if they are marked by  
epigenetic and transcriptional differences relative to integrants (Parfenov, Pedamallu et 
al. 2014). To summarise, the establishment of a cellular state with constitutive E6/E7 
expression leads to phenocopying the effect of genetic disruption and the subsequent 
loss of TP53 and pRb. This, as with other dsDNA viruses, is consistent with requirement 
for host cell replication machinery for viral replication, and the subsequent need to 
block a TP53 response, also evident in other oncogenic viruses like KSHV, Hepatitis B, 
EBV and SV40, that all encode TP53 degrading proteins (Munoz-Fontela, Garcia et al. 
2007) 
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1.9 Basic genome structure and organisation in the human genome.  
DNA in eukaryotes, including humans, is closely associated with nucleosomes. Each 
nucleosome is made of an octameric histone heteropolymer consisting of 2 copies of 
histones H2A and H2B, and two each of H3 and H4, and DNA that is not directly wrapped 
around histones is associated with linker Histone H1. Each Histone molecule has a head 
and outwards-facing amino acid tails with residues that are modified postranslationally, 
leading to varying states of compaction and relaxation. Cellular chromatin is on a more 
global level found folded in three dimensions, and patterns of binding of the insulator 
protein CTCF result in the genome being divided into domains or gene compartments 
and high levels of looping (Sanborn, Rao et al. 2015). On a much smaller scale, genes 
have upstream promoters that enable the assembly of RNA-polymerase complex and 
subsequent transcription of the gene downstream, which following splicing of intronic 
sequences and translation culminates in protein synthesis. Chromatin looping facilitates 
interactions between enhancers and promoters despite large linear distances (up to 
500kb) separating these elements and can fine-tune gene expression(Mora, Sandve et 
al. 2015). 
There are multiple biological processes that impact the organisation of the genome and 
chromatin compaction, facilitating changes in gene expression programmes. These 
include changes that directly modify DNA, such as DNA methylation, or histone 
modifications that, by altering the charge on the amino acid tails of histones, can affect 
compaction. Other epigenetic modifications involve deposition of novel histone variants 
or depletion of nucleosomes through the activity of nucleosome remodelling ATPases.   
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1.10 Histone modifications and chromatin states regulate gene expression 
When investigating the regulatory architecture of the human genome, the ENCODE 
project consortium profiled multiple histone modifications (Table 1) that contained 
enough information to account for variations in gene expression to a sufficiently high 
degree of accuracy (Regression R ~ 0.78 in K562 cells) (ENCODE 2012) . 
Histone 
modification or 
variant 
Signal 
characteristics 
Putative functions 
H2A.Z Peak Histone protein variant (H2A.Z) associated with regulatory elements with 
dynamic chromatin 
H3K4me1 Peak/region Mark of regulatory elements associated with enhancers and other distal 
elements, but also enriched downstream of transcription starts 
H3K4me2 Peak Mark of regulatory elements associated with promoters and enhancers 
H3K4me3 Peak Mark of regulatory elements primarily associated with 
promoters/transcription starts 
H3K9ac Peak Mark of active regulatory elements with preference for promoters 
H3K9me1 Region Preference for the 5′ end of genes 
H3K9me3 Peak/region Repressive mark associated with constitutive heterochromatin and 
repetitive elements 
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H3K27ac Peak Mark of active regulatory elements; may distinguish active enhancers 
and promoters from their inactive counterparts 
H3K27me3 Region Repressive mark established by polycomb complex activity associated 
with repressive domains and silent developmental genes 
H3K36me3 Region Elongation mark associated with transcribed portions of genes, with 
preference for 3′ regions after intron 1 
H3K79me2 Region Transcription-associated mark, with preference for 5′ end of genes 
H4K20me1 Region Preference for 5′ end of genes 
Table 1: Summary of Histone modifications profiled by ENCODE and known functional 
associations. Table from (ENCODE 2012)                
Mutations in chromatin modifiers have been widely documented in cancer, with nearly 
34 known regulatory factors dysregulated in ways consistent with a driver role across a 
large series of tumours from multiple sites (Gonzalez-Perez, Jene-Sanz et al. 2013). Other 
studies have documented that major Nucleosomal-remodelling ATPases such as 
members of the SWI/SNF complex are widely mutated (Kadoch, Hargreaves et al. 2013). 
Beyond the direct mutagenesis of chromatin modifiers, a range of pro-oncogenic 
dysregulation of epigenomic control is also achieved by substrate level modification, 
including transcription-factor binding associated super-enhancer formation through core 
transcriptional coactivator recruitment through intronic mutations (Mansour, Abraham 
et al. 2014) or changes in genome-wide histone deposition and transcriptional antigen 
through trapping chromatin modifiers, as evident in H3k27 mutations in paediatric 
gliomas (Lewis, Muller et al. 2013). 
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1.11 An overview of DNA methylation. 
DNA methylation, involving the methylation of the 5th carbon atom of cytosine to yield 
5-methylcytosine, has been one of the most well characterised epigenomic 
modifications. DNA methylation is induced by the activity of DNA methyltransferases, of 
which there are three main examples in humans; the maintenance DNA 
methyltransferase DNMT1 and the de-novo methyltransferases DNMT3a and DNMT3b. 
 DNA methylation, depending on the genomic context of the modified bases, has been 
shown to influence gene expression in contrasting ways. Traditionally, the 
hypermethylation of promoters in CpG islands (Regions of high CpG density that remain 
unmethylated and may be proximal to genes) has been implicated in the silencing of 
gene expression (Newell-Price, Clark et al. 2000), whereas the methylation of gene 
bodies has been associated with increased transcriptional activity (Yang, Han et al. 
2014). More recent studies have highlighted that the impact of methylation on gene 
silencing is even more strongly evident at enhancers relative to promoters; distinct 
patterns of hypomethylation have been found around so-called “super-enhancers” and 
methylation of CTCF binding sites has been shown to result in novel, pro-oncogenic 
enhancer-promoter interactions (Flavahan, Drier et al. 2016).   
The ability of DNA methylation to act at long distances in regulating transcription of 
genes that are situated several thousands of base pairs downstream, comprising 
promoter-downstream Correlated Regions (pdCRs), has also been documented through 
bisulfite sequencing based studies of tumours (Hovestadt, Jones et al. 2014) .  
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Additionally, DNA methylation has been sometimes shown to mark genes whose status 
is converse to what is canonically expected, serving as a marker for accessibility of DNA 
methyltransferases, and consequently transcriptional machinery, to transcribed genes 
and appearing in the formation of distinctive regions called DNA methylation valleys 
(Hovestadt, Jones et al. 2014). These discoveries, taken together, identify DNA 
methylation as a potent orchestrator of gene expression programmes in cellular growth 
and function.   
DNA methylation has been implicated in pathogenesis in a wide variety of cancer and 
non-cancer disorders, including Rett’s Syndrome (Weaving, Ellaway et al. 2005) and 
fragile X-syndrome (Brasa, Mueller et al. 2016). Particularly in cancer, evidence has 
steadily accumulated for the role of DNA methylation in modulating tumourigenesis.  
De Carvalho et al (De Carvalho, Sharma et al. 2012) demonstrated using DNMT1 & 
DNMT3b double-knockout HCT116 cells the existence of methylation-silenced genes 
whose expression was cytotoxic and preserved methylation states in clinical samples of 
tumours, suggesting methylation events could be drivers of cancer-cell survival.  
Additional studies since have shown that low doses of demethylating agents such as 
decitabine and aza-citidine can be used to impair the long term growth of cancer cells, 
through reactivating methylation-silenced tumour suppressor genes (Tsai, Li et al. 
2012)and targeting gene-body methylation of oncogenes(Yang, Han et al. 2014), as well 
as triggering an interferon-directed immune response in putative cancer-stem-cells by 
reactivating the expression of endogenous retroviral elements (Roulois, Loo Yau et al. 
2015).  
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The biological role of DNA methylation may extend beyond the regulation of levels of 
gene expression, for instance, it has been suggested that gene body methylation may 
regulate exon inclusion mediated by MeCP2 binding (Maunakea, Chepelev et al. 2013). 
Similarly, epigenetic resetting in neural stem-cell cultures through the induction of 
pluripotency demonstrated the existence of some lineage-specific methylation changes 
required for the successful engraftment and growth of cancer-stem-cells (Stricker, Feber 
et al. 2013).  
DNA methylation has also been shown to play a role in the genomic evolution of cancer. 
Large concordant losses of methylation as tissues acquire increasing degrees of 
malignant transformation has been described in multiple tissue types, including 
hypomethylation (and methylation hypervariability) of tissue specific genes that tend to 
show hypervariable expression in cancer (Timp, Bravo et al. 2014).  
Analysis of multiregion methylation data in prostate cancer has highlighted DNA 
methylation variability across individuals (Brocks, Assenov et al. 2014), and stochastic 
methylation changes in Chronic Lymphocytic Leukaemia (CLL) have been shown to track 
with survival (Landau, Clement et al. 2014). Studies in additional tumour types, such as 
glioblastoma multiforme (Ceccarelli, Barthel et al. 2016) , ependymomas (Mack, Witt et 
al. 2014) and paediatric Central Nervous System (CNS)(Sturm, Orr et al. 2016) tumours 
have established the presence of distinct methylation subtypes with altered implications 
for prognosis, such as a CpG Island Hypermethylator Phenotype (CIMP) being indicative 
of better-prognosis GBM and worse prognosis in ependymomas, collectively suggesting 
that DNA methylation patterns serve as useful features for tumour class discovery with 
implications for clinical practise.  
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1.12 Additional cellular changes beyond constitutive E6/E7 expression are required for 
progression.   
In addition to the critical dysregulation of p53 and pRb by the viral oncoproteins E6 and 
E7, additional mutations, gene expression, copy number and epigenetic changes 
characterise HPV driven cancers. DNA sequencing studies of HPV positive HNSC carried 
out in the laboratory revealed a very high frequency of mutations in PIK3CA (mutation or 
amplification) and PTEN and FBXW7 loss in HPV positive tumours as well as copy number 
changes in SOX2 (Lechner, Frampton et al. 2013) .  TCGA-led exome sequencing 
identified PIKC3CA (53%) as the predominant driver in HPV+ tumours, followed by EP300 
(14%) and NOTCH1 (11%). Other mutation-sequencing efforts in Cervical Cancers and 
Head and Neck Cancers have also identified sets of recurrently mutated genes in HPV+ 
tumours, consistent with a driver role (Agrawal, Frederick et al. 2011, Ojesina, 
Lichtenstein et al. 2014).   In Ojesina et al (Cervical cancers), PIK3CA (14%), PTEN (6%) 
and STK11(4%) were present in 14%, 6% and 4%, EP300 (16%), FBXW7 (15%), HLA-B 
(9%), MAPK1 (8%) and NFE2L2 (4%) were significantly recurrent in squamous 
carcinomas, while in adenocarcinomas, PIK3CA (16%), KRAS (8%) , ELF3 (13%) and CBFB 
(8%) were reported, suggesting some tissue-of-origin associated heterogeneity. 
A host of other studies have reported distinct transcriptional changes in HPV driven 
cancers, most notably a study that investigated transcriptomes in HPV+ HNSC vs HPV- 
HNSC and normal tissue and CESC and normal tissue (Pyeon, Newton et al. 2007). Their 
findings suggested that HPV induces a cascade of gene expression changes involving a 
large number of cell-cycle genes.  
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Additionally, a DNA methylation signature that could distinguish HPV positive HNSC from 
HPV negative HNSC has been reported, and signature probes were shown, upon 
multidimensional scaling, to overlap with cervical cancer methylomes (Lechner, Fenton 
et al. 2013). Multiple concordant lines of evidence therefore point to the importance of 
epigenetic processes that alter gene expression in the progression and the development 
of HPV driven cancers.  
The identification of critical mediators of such processes that were specific to HPV 
positive tumours would therefore stand to serve as the basis for the development of 
effective targeted therapeutics and further the understanding of HPV-driven 
tumourigenesis. 
Several proteins involved in modifying chromatin and regulating gene expression have 
been found to be essential for the survival of HPV positive cancer cells. Histone 
demethylases KDM6A and KDM6B are induced by E7 and their depletion has been 
shown to suppress growth in CaSki, an HPV positive cervical cancer cell line (McLaughlin-
Drubin, Crum et al. 2011), this has more recently been shown to be by way of being 
required for p16 overexpression that prevents cell death through a yet unknown Cyclin 
D1 associated pathway (McLaughlin-Drubin, Park et al. 2013). Additionally studies have 
shown the existence of distinct cellular methylation profiles in HPV driven tumours, 
albeit on an individual tissue level, in HNSCs (Lechner, Fenton et al. 2013) and Penile 
Cancers (Feber, Arya et al. 2015).   
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1.13 HPV-specific pan-tissue transcriptional and epigenomic profiles - a background.  
Multiple studies, including those describing datasets that I used for meta-analysis (See 
2.1) have identified transcriptional changes in HPV transformed tissues relative to either 
normal controls or HPV- cancers. Only one of these studies however, investigated both 
CESC and HNSC (Pyeon, Newton et al. 2007), while two previously published meta-
analyses (Buitrago-Perez, Garaulet et al. 2009, Kaczkowski, Morevati et al. 2012), as well 
as a pilot project I carried out for a Master’s thesis, were based on the direct comparison 
of lists of significant differentially expressed genes from different studies, selecting 
genes that were associated with HPV-mediated transformation in a predetermined 
number of published studies as being HPV associated, and were therefore power limited 
by the sample numbers of the individual studies.  
A recent meta-analysis used a more sophisticated statistical approach but was restricted 
to integrating published studies of CESC expression and copy number alterations (Mine, 
Shulzhenko et al. 2013) and another analysis of HPV+ samples across 12 tumour types 
from the TCGA PANCAN12 dataset, despite the lack of normal samples or other models 
of HPV+ transformation, indicated crucially for my analysis that HPV+ tumours across 
tissue sites were closer to each other than to HPV- samples arising in similar tissues 
(Tang, Alaei-Mahabadi et al. 2013). Studies on epigenetic similarities across tissue sites 
have only been carried out on a very small scale; (Lechner, Fenton et al. 2013) 
demonstrated similarities across tissue sites but this was limited by the low resolution of 
the Illumina 27k methylation array. (Feber, Arya et al. 2015) used a simple overlap 
criterion between PeCa (Penile Carcinoma) and HNSC.  
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Core Hypotheses 
In this thesis, I test the following hypotheses  
A) HPV-driven cancers share common molecular profiles independent of the tissues 
from which they arise. These molecular profiles are reflective of HPV biology, and 
their establishment is actively shaped by HPV oncoproteins (Chapters 3-5) 
B) If HPV can establish tissue independent molecular profiles, it follows that 
variation in HPV should result in molecular differences between tumours caused 
by different HPV types, with potential clinical impact (Chapter 6). 
C) Microenvironmental influences (including the immune microenvironment) shape 
molecular profiles, tumour evolution and clinical behaviours in tumours despite 
common aetiology (Chapters 3 and 7). 
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Chapter 2: Methods  
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2.1 Meta-analysis to identify a pan-tissue HPV-specific transcriptional profile.  
Microarray studies featuring HPV driven transformation with raw data available from EBI 
Array Express carried out on the Affymetrix hgu133plus2 or U133A platforms (Table 2) 
were identified. Datasets were rma normalised using the affy bioconductor package 
(Gautier, Cope et al. 2004) and reduced to the 22277 probes found on both hgu133plus2 
and u133a arrays. Initial feature selection was carried out by combining effect sizes 
using moderated limma t-tests with the R package MetaMA  (Marot, Foulley et al. 2009). 
I selected features with Benjamini-Hochberg adjusted P-values (the false discovery rate, 
referred to as "FDR" hereafter) (Benjamini) of 0.01 or less and median fold change 
cutoffs (median of median fold changes across each dataset)  above 2. 
2.2 Validation of classification tissue independence using an expression dataset from 
engineered tMSCs. 
Raw expression data for MSCs serially transformed with the addition of hTERT, HPV 
oncogenes E6 and E7, SV40 small T antigen and mutant HRAS were downloaded from 
EBI Array Express (M-EXP-563) and RMA normalised. The dataset was reduced to the 
179 HPV associated probes identified by our meta-analysis. Hiearchical clustering was 
carried out using Euclidean distance average linkage separation of samples based on the 
presence of HPV oncoproteins and cellular oncogenes from E6/E7 negative tMSCs was 
observed. The robustness of the clusters was verified using multiscale bootstrap 
resampling (10,000 samples) with the pvclust R package (Suzuki and Shimodaira 2006).  
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 Accession Sample Description Comparisons made Sample numbers Platform 
E-GEOD-
6791 (Pyeon, 
Newton et 
al. 2007) 
Clinical samples of 
HNSC and normal oral 
epithelium, Cervical 
Cancer and normal 
cervical epithelium. 
CESC vs Normal 
Cervical 
Epithelium. HPV 
positive HNSC vs 
HPV negative HNSC 
and Normal oral 
epithelium  
20 CESCs, 8 Normal 
cervical epithelium.  
26 HPV negative 
HNSCs, 16 HPV 
positive HNSCs, 14 
normal oral 
epithelium. 
Hgu133plus2 
E-GEOD-
15156 
(Kravchenko-
Balasha, 
Mizrachy-
Schwartz et 
al. 2009) 
Immortalised 
Keratinocytes. 
Uninfected, HPV 
infected early passage, 
late passage and 
Benzopyrene treated 
late passage cells. 
Early passgage, 
Late passage and 
Benzopyrene 
treated late 
passage infected 
keratinocytes  vs. 
uninfected 
Keratinocytes 
3 each of 
uninfected 
keratinocytes, early 
passage , late 
passage and 
benzopyrene 
treated late 
passage 
keratinocytes 
HG_U133A 
E-GEOD-
3292 
(Slebos, Yi et 
al. 2006) 
Clinical samples of HPV 
positive and HPV 
negative HNSC. 
HPV positive vs. 
HPV negative HNSC 
 
27 HPV negative 
HNSC,  9 HPV 
positive HNSC.  
Hgu133plus2 
E-GEOD-
5563 
(Santegoets, 
Seters et al. 
2007) 
Clinical samples of 
Vulval Intraepithelial 
Neoplasia and normal 
Vulval epithelium 
VIN vs. Normal 
10 Normal vulval 
epithelial samples, 
9 intraepithelial 
neoplasia. 
Hgu133plus2 
E-GEOD-
9750 
(Scotto, 
Narayan et 
al. 2008) 
Cervical Cancer cell 
lines, Cervical cancer 
clinical samples and 
normal cervical 
epithelium. 
Cancer vs. normal 
33 CESC clinical 
samples, 9 CESC 
cell lines, 24 normal 
cervical epithelium. 
HG_U133A 
E-GEOD-
7803 (Zhai, 
Kuick et al. 
2007) 
Cervical cancer clinical 
samples, high grade 
premalignant lesions 
and normal cervical 
epithelium. 
Cervical 
cancer/HSIL vs. 
Normal 
10 normal cervical 
epithelium, 7 HSIL, 
24 CESC clinical 
samples.  
HG_U133A 
E-GEOD-
24089  
HNSC and CESC cell 
lines 
HPV positive vs 
HPV negative cell 
lines.  
2 HPV positive, 2 
HPV negative. 
Hgu133plus2 
Table 2: Datasets used to define a pan-tissue HPV signature by meta-analysis using effect 
size combination.  Dataset identifiers apply to EBI Array Express/ Gene Expression Omnibus. 
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The process was repeated with a previously published signature defined by the manual  
comparison of published lists of differentially expressed genes associated with HPV-
mediated transformation (Buitrago-Perez, Garaulet et al. 2009) to facilitate direct 
comparison. 
The stability of clustering in the training datasets was estimated by constructing a 
misclustering index. The index was constructed by using consensus PAM (Partitioning 
Around Medoids) clustering to find the optimum number of clusters for each dataset via 
an interface written using the clusterCons package.  The number of clusters with the 
highest robustness, estimated using the clRob function, was used to group samples and 
the index was defined as the percentage of HPV+ samples that were classified outside 
the majority HPV+ cluster.  
2.3 Validation of feature selection using TCGA RNA-seq data. 
Level 3 RNAseqV2 Gene level normalised data were downloaded from the TCGA data 
portal for 566 samples (Normal head and neck, and HNSC) and parsed into a feature by 
sample matrix using a custom R function. HPV status for HNSC samples was obtained 
from Xiaoping Su (Personal correspondence).  
Data were transformed using the variance-stabilizing-transformation function in the 
DESeq2 package while controlling for the covariates of HPV status and cancer/normal 
status (Love, Huber et al. 2014). Building and testing classifiers and further feature 
selection were carried out using the caret R package. Classification performance was 
estimated using 10 iterations of 10 fold Cross-Validation using a Random Forest model 
with an mtry value set to 1/3 the size of the feature-set used for classification.  
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Given the unbalanced nature of the dataset Cohen's Unweighted Kappa was used as the 
performance metric. Performance against randomly sampled features was evaluated 
using identical tuning and cross-validation parameters to preserve within-resample 
correlations and 10 sets of 157 randomly drawn genes not in our signature. The meta-
signature was also compared to two previously defined signatures; one by list 
comparison (Davies, Wagstaff et al. 2013)  and one by supervised analysis of the TCGA 
HNSC dataset (Tang, Alaei-Mahabadi et al. 2013) using distributions of Cohen's Kappa 
from 10 iterations of 10-fold cross-validation and the statistical significance of 
differences in distributions was estimated using Wilcoxon's Rank Sum test with 
Benjamini-Hochberg multiple testing correction.  
 2.4 Downstream Analysis using Ingenuity Pathway Analysis. 
I performed a core analysis using Ingenuity Pathway Analysis (Qiagen) referring to 
experimentally confirmed and high-confidence predicted interactions. I identified 
canonical pathways, activated and deactivated predicted upstream regulators and 
molecular networks associated with the metasignature.  
2.5 Modelling the HPV signature in the context of general malignant transformation. 
Along with HNSC RNA-seq data described above, a comprehensive dataset of other 
tumour types with at least five normal samples from the TCGA, including Lung 
Squamous Cell Cancers, Lung Adenocarcinomas, Colorectal Adenocarcinomas, Breast 
Adenocarcinomas, Prostate Adenocarcinomas, Kidney Clear Cell and Papillary Cancers, 
Hepatocellular carcinomas, Bladder Adenocarcinomas and Glioblastoma Multiforme 
samples was established from SAGE Synapse (Omberg, Ellrott et al. 2013), comprising a 
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combined dataset of 6354 samples.  A linear model with HPV status, Cancer/Normal 
status and tumour type was fit using limma-trend (Law, Chen et al. 2014) on quantile 
normalised log2 counts per million values of gene expression and differentially 
expressed genes (DEGs) were defined at a 2 fold-change and FDR < 0.01.  
2.6 Analysis of Methylation patterns by anatomic subsite 
Methylation data were downloaded in the form of raw IDAT files for 464 HNSC with 
known HPV status and were then SWAN normalised. A methylation signature was then 
derived exclusively from the OPSCCs to discriminate between HPV+ and HPV- tumours 
using a custom function based on limma, with significant probes defined at a delta-Beta 
value of 0.4 and an FDR of 0.001 or less.  
A Random Forest model was fit and predictions of HPV status across the entire dataset 
(OPSCC and non-OPSCC) were made using the majority class vote across 10 iterations of 
10-fold Cross Validation when samples where held-out. The “mtry” parameter (number 
of features bagged per tree) for Random Forests was set to 1/3 the size of the signature 
features and forests were grown with 500 trees.  
2.7 Analysis of genomic profiles  
Segmented copy number data from Affy SNV arrays were downloaded from the TCGA 
data portal (Level 3) for 545 samples, CCND1 amplifications (segment mean > 0.1) and 
CDKN2A deletions (segment mean < -0.1) were then called.  
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Somatic mutation MAF files were downloaded for exome-sequenced data (n= 528 ) from 
the TCGA data portal, and samples were checked for mutations in TP53 and CDKN2A. 
Proportions of these genomic alterations were then defined for combinations of HPV 
status (as determined for RNA-seq analyses) and anatomic subsite.  
2.8 Analysis of survival associations with subsite in the TCGA cohort. 
Clinical data were downloaded from the UCSC Cancer Browser. Univariate Cox 
regression was used to test associations between anatomic subsite (dichotomised as 
OPSCC/non-OPSCC) within whitelisted HPV+ tumours (Samples misclassified by both 
Methylation and Expression signatures with low E6/E7 expression were excluded). 
Subsite specific molecular profiles were analysed by searching for MVPs using the 
aforementioned thresholds and DEGs at a threshold of 2FC, FDR < 0.01.   
2.9 Analysis of immune infiltration and outcomes 
Two distinct approaches were used to estimate immune cell infiltration in HPV+ 
tumours. CD4 (helper T-cell) and CD8A and CD8B (Infiltrating T-lymphocyte) reads were 
extracted from the Variance-stabilised RNA-seq data to serve as a surrogate for 
infiltrating lymphocyte content.  
Wilcoxon’s tests were used to estimate statistical significance of difference by HPV 
status and anatomic subsite, with Benjamini-Hochberg correction for multiple testing. 
Independently, H&E digital pathology slides were evaluated on a blinded basis by Gareth 
Thomas, a pathologist (University of Southampton) to estimate TIL scores and 
morphology (basaloid/poorly differentiated vs keratinising/moderately differentiated).  
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Assessable samples were binned into three TIL categories (Low, Moderate and High) and 
associations between TIL content and anatomic subsite were tested for using the 
Cochran-Armitage test for trend.  
The activation status of TILs was estimated based on the expression of Granzymes 
(Granzyme A,B,H,K and M), Perforin and IL2 using Wilcoxon’s Rank Sum Test with 
Benjamini Hochberg correction for multiple-testing. A manually curated list of Immune 
Checkpoint Molecules, the aforementioned effectors, and lymphocyte markers was used 
to consensus cluster HPV+ tumours using Partitioning Around Medoids with 2:5 
candidate clusters with the clRob function in the clusterCons R package used to select 
the most robust cluster.   
Associations between immune clusters and anatomic subsite were tested using Fisher’s 
Exact Test. Multivariate Cox regression was used to estimate the influence of immune 
transcription patterns after controlling for T-stage (dichotomised into > 3 / < 3), lymph-
node status (dichotomised into > N2b / < N2b), age at diagnosis and smoking status 
(pack years > 10 / pack years < 10) and anatomic subsite. Smoking, T-stage and node 
categories were defined on the basis of previous work identifying these as prognostic 
factors in HPV+ OPSCC (Ward, Thirdborough et al. 2014) (Ang, Harris et al. 2010).  
Additional validation was carried out by clustering HPV+ samples on the basis of gene-
modules defined to be operational in Squamous Cell Carcinomas in previously published 
work (Ottensmeier, Perry et al. 2016). Four modules of 20 genes each (M1, M5, M6, M9) 
that were associated with HPV status were used. Associations with survival and 
anatomic subsite were tested as above.  
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2.10 Exome-data preprocessing and curation for studies of APOBEC-mediated 
mutagenesis.  
Level 3 somatic mutation data in Mutation Annotation Format (MAF) were retrieved 
from the TCGA data matrix for 506 HNSCs and 191 CESCs, along with clinical data, which, 
for HNSC patients, included smoking history in pack-years and age. HPV status was 
allocated using the presence or absence of viral transcripts as reported in Tang et al 
(Tang, Alaei-Mahabadi et al. 2013). E6 and E7 RNA seq read counts were obtained by 
personal communication with Xiaoping Su for transcript + HNSC. 
Somatic mutation data for exomes from 213 virus-associated hepatocellular carcinomas 
(HCC) were downloaded from the International Cancer Genome Consortium's data 
portal (Project - LINC-JP) and were converted to be compatible with TCGA MAF files 
using a custom function. MAF files for 25 EBV+ (Epstein Barr Virus) Stomach 
Adenocarcinomas were obtained using the TCGA data portal. Putative driver genes were 
identified using Firehose analysis reports from the Broad Institue Genome Data Analysis 
Centre using MutSig CV v2.0). Duplicate entries in .MAF files were eliminated and 
mutations not mapping to the standard chromosomal complement were excluded. 
Mutations that were not SNVs were subsequently filtered.  
2.11 Quantification and examination of patterns of APOBEC mediated mutagenesis.  
 
Unsupervised signature extraction using Non-negative Matrix Factorisation.  
The DeconstructSigs R package (Rosenthal, McGranahan et al. 2016) was used to model 
mutations in trinucleotide contexts in SNVs in the TCGA dataset. Data were normalised 
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to trinucleotide frequency in exomes and per-sample weights were extracted. The 
proportions of mutations attributed to different mutational signatures was then used to 
obtain, based on the overall number of mutations in the sample, the fraction of 
mutations attributable to APOBEC-associated WTSI (Wellcome Trust Sanger Institute) 
signatures (Signatures 2 and 13) and not.  
Supervised signature extraction 
The nucleotide contexts of SNVs were extracted using a custom function written by Dr 
Stephen Henderson (UCL Cancer Institute, Bill Lyons Informatics Centre). The preceding 
and succeeding bases were retrieved from the BSgenome.Hsapiens.UCSC.hg19 
bioconductor package and were classified as APOBEC mutations if they occurred in the 
TCW->TKW context on either strand (K=T/G, W=T/A). While APOBEC-mediated 
mutagenesis is also known to generate TCG->TKG mutations, this shares similarities with 
mutations produced by the spontaneous deamination of methylcytosine and hence 
wasn't included in the definition of an APOBEC-mediated mutation.  
Calculating significance of enrichment using background likelihood of TCW mutagenesis.  
As another method of testing for associations of APOBEC-mediated mutagenesis with 
HPV, enrichment for TCW-TKW mutations were established relative to the background 
fraction of cytosines in and out of the TCW context obtained from 41 base pair windows 
around each SNV using Fisher's exact test. Bootstrapping was performed to define the 
95% Confidence Intervals of the enrichment distributions for HPV+ and HPV- HNSCs and 
a Wilcoxon's test was carried out on the trimmed distributions to ascertain the 
significance of shifts. 
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 Generalised Linear Modelling 
Generalised Linear Models were fitted to the distributions of a) TCW->TTW mutations b) 
TCW->TGW mutations and c) Fraction of mutations in the unsupervised cluster that 
resembled the candidate APOBEC signature reported in Alexandrov et al ((Alexandrov, 
Nik-Zainal et al. 2013) against HPV status, age and smoking history where available using 
a binomial distribution function through the glm R function. Odds ratios and 95% CI 
estimates were retrieved using a custom R function.  
2.11 Testing whether APOBEC mediated mutagenesis is a generalised antiviral 
response. 
TCW->TKW fractions were computed using the pipeline described above and mutation 
contexts were visualised around cytosine sites using sequence logos.  Distributions were 
compared using Wilcoxon’s Rank Sum test.  
2.12 Analysis of Driver Mutations 
Examination of mutational trends in candidate drivers 
To ascertain if trends seen in whole-exome data were maintained across putative driver 
mutations, MAF files were reduced to genes identified as significant driver mutations (q 
value < 0.05) using MutSig analysis as documented in the relevant TCGA Firehose 
reports. Supervised analysis was carried out as for the whole exome data to compute 
fractions of candidate APOBEC mutations. Distributions were compared between 
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Exome-wide estimates and MutSig-specific estimates for HNSC (HPV+ and HPV-) and 
CESC using Wilcoxon’s Rank Sum Test.  
Analysis of PIK3CA Hotspot Mutation Distributions  
Enrichment for TCW->TKW mutations in PIK3CA in HPV+ tumours relative to HPV- 
tumours was tested using Fisher’s Exact Test. To test the association between a skew 
towards PIK3CA Helical Hotspot mutations and increased APOBEC-activity, PIK3CA 
mutation data were downloaded from the cBio portal (Cerami, Gao et al. 2012) for 
cancer genomics for tumours across eight tumour types (Breast Carcinoma (BRCA), 
Bladder Urothelial Carcinoma (BLCA), Colorectal Adenocarcinoma (COADREAD), CESC, 
HNSC, Uterine Corpus Endometrial Carcinoma (UCEC) and Stomach Adenocarcinoma 
(STAD).  
For each tumour type, the number of PIK3CA mutations mapping to either the helical 
and kinase hotspots were summarised and converted to proportions of all PIK3CA 
hotspot mutations (Helical = E542K/E545K, Kinase= H1047) found in the tumour type.  
Associations between helical mutation hotspot preference and APOBEC-mediated 
mutagenesis was tested in two ways: binomial GLMs fitted with tumour type and 
mutated hotspot as variables and finally a conditional independence test using the coin 
R package with tumour type as a blocking factor to compare differences in TCW -> TKW 
mutation fractions between helical hotspot and kinase hotspot mutants.  
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2.13 Examination of factors modulating APOBEC mediated mutagenesis 
Viral gene transcription. 
Normalised read counts for E6 and E7 transcripts were obtained by personal 
correspondence with Xiaoping Su. Associations between APOBEC-mediated mutagenesis 
and viral gene expression were tested using Spearman's rank correlation between 
normalised read counts and TCW-mutation fraction. Correlations between E6/E7 
expression and APOBEC3B expression were assessed using Spearman's rank correlation. 
APOBEC-family members were tested for differential expression using Wilcoxon’s Rank 
Sum Tests. Multiple testing correction was carried out using the Benjamini-Hochberg 
approach.  
Subtype specific associations with overall mutational load 
The relationship between TCW and non-TCW mutational burden was modelled using 
ANOVA using the leaps R package.  Models were fit with total number of TCW mutations 
as the response variable with non-TCW mutation total and HPV status as covariates, 
with both interactive and additive layouts. The adjusted R2 value was used to select the 
best model.  
Associations with expression of APOBEC3 family genes 
Read counts were isolated for APOBEC family members from the RNA-seq matrices 
generated for prior analyses of gene expression and transformed into log2 counts per 
million. Differential expression by HPV status was estimated using Wilcoxon's Rank Sum 
tests and correlations with expression were tested using Spearman's Rank Correlation.  
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2.14 Assembly of a dataset to define HPV-associated methylation profiles. 
In order to uncover patterns of DNA methylation changes that marked HPV-driven 
tumourigenesis, I assembled an initial dataset of 844 samples with putative associations 
with HPV related cancers, including HPV- tumours from the head and neck, and normal 
cervix and head and neck cancers from the TCGA, and normal cervix samples from 
another published study (Table 3) 
Raw IDAT files were between-array- normalised using the FunNorm function in the minfi 
Bioconductor package (Aryee, Jaffe et al. 2014), with initial noob correction of intensities 
using dye-swap (Triche, Weisenberger et al. 2013). Beta values were then retrieved and 
corrected for probe-type differences using BMIQ normalisation (Teschendorff, Marabita 
et al. 2013) using 10,000 reference probes for EM fitting . 794 out of the 
aforementioned 844 samples had matching RNA-Seq data.  
2.15 Preprocessing and Normalisation of validation datasets 
I obtained raw IDAT files for a previously published comparison of HPV+ and HPV- 
oropharyngeal cancers, HPV+ and HPV- cell lines and Penile Carcinomas. Each of these 
datasets were preprocessed separately, using Functional Normalisation and BMIQ 
normalisation with 10000 reference probes. 
2.16 Identification of Methylation Variable Positions (MVPs) 
I used linear modelling using the limma package with tissue and cancer/normal status as 
covariates, followed by empirical bayes error estimation while correcting for mean-
variance trend, to obtain a list of probes associated with HPV status.  
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Tissue type Method of HPV Status 
Detection 
Sample 
Breakdown 
Data Source  
TCGA HNSC Viral Transcript Detection 
(VirusSeq, courtesy X.Su ) 
50 normal 
68 HPV+  
434 HPV- 
TCGA Data Portal  
TCGA CESC Viral Transcript Detection 
(Tang, Alaei-Mahabadi et 
al. 2013) + in-house 
analysis (courtesy 
S.Henderson) 
309 cancer 
3 normal  
TCGA data portal 
Normal Cervix Samples Normal samples presumed 
HPV -  
16 normal  
 
(Farkas, Milutin-
Gasperov et al. 2013) 
Penile Cancers (PeCa) P16 staining + E6 ISH 26 in total, 7 
HPV+ ( 4 > 1 
copy/ cell, 3 
< 1 copy/cell)  
Raw data courtesy 
Andrew Feber 
Cervical Cancers  
(Norway)  
RNA-seq detection of viral 
transcription. Normal 
samples presumed 
negative. 
29 Normal, 
77 tumours. 
In house, for samples 
genomically profiled 
in (Ojesina, 
Lichtenstein et al. 
2014) 
Table 3: HM450k datasets used for constructing and validating an HPV-associated pan-
tissue methylation signature. Discovery set components in blue text. 
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Adjusted P values were recalculated using a custom wrapper to the two-step BH (TSBH) 
procedure as implemented in the multtest package, a method shown to perform well 
under the presence of correlated test statistics (Benjamini, Krieger et al. 2006), to 
achieve control of the False Discovery Rate under multiple testing.  MVPs were defined 
at a median beta value difference (dB) of 0.2 and an FDR of 0.001. 
2.17 Development of fDMR: an annotation-based approach to call Differentially 
Methylated Regions (DMRs). 
fDMR was developed as a derivative of the Probe Lasso approach(Butcher and Beck 
2015) implemented in the ChAMP (Morris, Butcher et al. 2014)Bioconductor package. In 
the fDMR approach, probes are grouped into functional regions (5’ UTR, Promoter, 
Body, IGR and 3’ UTR) and functional regions that possess a minimum number of 
significant mvps under FDR and beta-value difference cutoffs then undergo Stouffer-
Liptak p.value combination of the raw P-values using a module of code originally 
implemented in the Probe Lasso DMR hunter (Butcher and Beck 2015), followed by 
further filtering to meet FDR (BH) and beta-value difference cutoffs at the DMR level.  
2.18 Identification of DMR signatures using fDMR.  
DMRs were defined as promoter/5'UTR/Gene Body regions with 3 MVPs at a delta-Beta 
of 0.20 at an FDR of 0.01 or less, and two.sided raw P-values were used for combination. 
DMRs were filtered for a median DMR deltaBeta of 0.20 and a DMR FDR (Benjamini 
Hochberg, BH) of 0.01 or less, non-significant MVPs in the same region were included for 
computation of false discovery rates of candidate DMRs. 
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2.19 Analysis of global trends in DNA methylation dysregulation. 
On a global scale, the CpG sites on the Illumina HM450k array are grouped into four sets 
of of CpG density-associated genomic features: CpG Islands, Open Sea probes, CpG 
Shelves and CpG Shores, and 7 sets of probe annotations.  Probes in the HPV associated 
MVP/DMR signatures were tested for enrichment of hypermethylation/hypomethylation 
in these categories relative to HPV negative samples using a binomial test with BH FDR 
correction, and for overrepresentation in the signature per se using Fisher’s exact test, 
again with BH FDR correction.   
To compare overall distributions, mean methylation values were retrieved for every 
sample within each group (normal/HPV- tumour/HPV positive tumour) within MVPs and 
across all probes, and comparisons were made using Wilcoxon’s Rank Sum Test.  
2.20 Pathway Analyses  
To evaluate the functional context of functional methylation changes, the lists of 
methylation-associated differentially expressed genes were passed through Ingenuity 
Pathway Analysis (QIAGEN) and subjected to canonical pathway analysis, upstream 
regulatory analysis and functional analysis using experimentally confirmed direct 
interactions in human tissues. Differentially expressed gene-sets were used instead of 
MVP/DMR associated probesets to prevent previously documented issues with the 
discovery of spurious associations when methylation array data are used instead.  
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2.21 Machine learning.  
For both the overall MVP and DMR associated signatures, Random Forest models were 
fit through a caret interface to the ‘randomForest’ function using 10 iterations of 10-fold 
cross validation with the .mtry parameter set to 1/3 of the total number of features, 
which is default.  
Class membership was estimated as the majority vote of the allocated class when 
samples were out-of-fold using a custom R function. Performance statistics and 
confusion matrices were generated using the caret R package. Kappa values, PPV (True 
Positives / Total Positive calls) and NPV (False Negatives / Total Negative Calls) 
2.22 Independent validation of signatures 
I used the predict function in the caret R package to estimate the performance of the 
model trained on the discovery set on additional datasets. Heatmaps were visualised 
using the aheatmap function from the NMF package with manhattan distance 
hierarchical clustering. These predictions were applied to Penile Cancer and Norwegian 
Cervical Cancers described in (Table 3). Analysis of batch effects in the Norwegian 
Cohort was compared using MDS (Multi-Dimensional Scaling) plots superimposing 
samples reduced to MVP-associated probes from this dataset onto the TCGA dataset. 
Overfitting analysis was carried out by checking if halving the size of the discovery set 
used for model fitting improved performance in the Norwegian dataset relative to out-
of-fold estimates on the half used for model fitting, and by checking if out-of-fold 
estimates from training on the Norwegian dataset using features derived from the 
discovery set were better than those returned by models trained on the former.  
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2.23 Analysis of distal regulatory changes.  
A BED file of known robust enhancers defined by bidirectionally transcribed loci through 
CAGE-seq across tissues, cell lines and primary cells, performed by the FANTOM5 
consortium was downloaded from the FANTOM5 portal (Lizio, Harshbarger et al. 2015). 
Enhancer-associated CpG sites on the 450k array were then identified using the 
findOverlaps function in the GenomicRanges Bioconductor package. Expression of these 
enhancers in tissues representative of those in methylome analyses was tested in CAGE-
seq enhancer BED files downloaded from the FANTOM5 portal for CaSki, HeLa, ME-180 
and D-98 (Cervical Cancer Cell Lines), Epidermal keratinocytes and Oral keratinocytes 
(Primary lines), Adult cervix pool (unfractionated tissue) and HSC-3, Ca9-22, SAS, and 
HO-1-n-1 (Head and neck cancer) cell lines. CAGE peak start sites were summed up in 
the intervals overlapping the corresponding enhancers to yield TPM (Tags Per Million) 
estimates of eRNA expression in enhancer-associated windows for confirmation these 
enhancers were active in at least some of the sample tissue types in the discovery set. 
Each enhancer was mapped to putative candidate genes by filtering for TSS-Enhancer 
correlation > 0.2, FDR < 0.01 in the FANTOM5 dataset, and this was used to define 
enhancer-MVP pairs for integration with expression data.  
2.24 Integration with matched Expression Data 
Expression data (RSEM fractional count estimates) were available for 794 samples 
overlapping the 844 used to discover methylation signatures. Values were transformed 
to log2 counts per million after quantile normalization and a linear model was fit with 
HPV status, tissue and cancer/normal status as covariates with a mean-variance trend fit 
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during empirical Bayes estimation to account for the non-trivial relationship seen 
between mean and variance in RNA-sequencing count data. Genes were defined as 
differentially expressed at 2-fold change at a BH-FDR of 0.01 or less. DMR and MVP-
controlled genes were then defined as epigenetically regulated if a) direction of 
expression change was inversely related to methylation and genes overlapped 
FANTOM5 enhancers or promoters or b) if non-enhancer gene-body probes were 
methylated and expression change was in the same direction.  
2.25 Pathway Analyses of Methylation Signatures  
Ingenuity Pathway Analysis was used to carry out Canonical Pathway Analysis, Diseases 
and Functions Analysis, Network Analysis and Upstream Regulatory Analysis with direct, 
experimentally confirmed interaction sets defined in Human tissues with Differentially 
Expressed Genes that were epigenetically regulated either by DMRs or MVPs.  
2.26 Focused Analysis of Interesting Candidate DMRs 
Correlations between gene expression and DNA methylation were tested out by 
comparing log2CPM values of RNA-seq data versus DMR-wise median methylation beta-
values for matched samples using Spearman’s Rank Correlation. P values were corrected 
for multiple testing using Benjamini-Hochberg correction.  
2.27 Analysis of Cell-of-origin signature patterns in HPV+ Cancers 
KRT7 DMR medians and KRT7 expression were compared between HPV+ HNSC 
(predominantly HPV16+), HPV16+ CESC, HPV18+ CESC and HPV45+ CESC using pairwise 
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Wilcoxon’s Rank Sum Tests. The gene set used to define Squamocolumnar Junction cells 
putatively identified as the source of Cervical Cancer was obtained from supplementary 
data from (Herfs, Yamamoto et al. 2012). HPV+ Tumours mapping to the 
aforementioned groups were clustered on the basis of this signature using PAM 
clustering, with robustness defined using the clRob function in the clusterCons R 
package. Binomial tests or Fisher’s exact tests were used to test for associations 
between Cell-of-origin signature allocations and sample group. Multiple testing 
correction was carried out using the Benjamini-Hochberg approach. 
2.28 Assembly of cervical cancer datasets for investigating taxonomic correlates of 
clinical behaviour.  
Level 3 RSEM upper-quartile normalised count values were downloaded from the TCGA 
data portal for 307 CESCs and parsed into a feature-by-sample matrix using an in-house 
package. Methylation beta values were extracted for this subset of samples from the 
discovery set established for the identification of Pan-tissue HPV methylome profiles. 
Clinical data were isolated from the TCGA data portal. The analysis was restricted to 
tumours histologically classified as Cervical Squamous Cell Carcinomas.  
2.28 Identification of HPV status. 
For a set of samples, HPV statuses were previously published in (Tang, Alaei-Mahabadi 
et al. 2013) and were used to allocate HPV type. For the remainder, RNA-seq fastq files, 
obtained from CGhub, were aligned using STAR to a reference index consisting of the 
genomes of the WHO12 high-risk types by Stephen Henderson. Samples were called 
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positive for a particular type if E6/E7 reads were detected, and if multiple types were 
present the most abundant type was assigned.   
2.29 Clade allocation and filtering for analysis.  
HPV Types were grouped into clades, as reported in the IARC monograph on HPV 
(Bouvard, Baan et al. 2014), and due to sample sizes available for each clade, analysis 
was carried out between two clades; with types 18, 45, 39, 70, 68, 59 comprising Clade 
A7 and types 67, 58, 33, 52, 31, 35, 16 comprising Clade A9. 
2.30 Modelling taxonomic correlates of F30 status. 
The hypothesis that there are molecular patterns and clinical differences between 
taxonomic groupings of HPV in cervical cancer was initially tested using a previously 
published 30 CpG based Nearest Shrunken Centroid classifier (Feber, Arya et al. 2015) 
(denoted F30 hereon) that had suggestive associations with HPV16 and better prognosis 
in a smaller set of TCGA CESC samples. 
 
 The extended CESC cohort was classified into F30 clusters using raw beta values 
following Functional Normalisation (i.e. not BMIQ-normalised to correct for probe-type 
bias). Binomial tests to estimate skews by clade (A7 vs A9) and types (HPV16, HPV45, 
HPV18) relative to F30 status against a null hypothesis of no preference for F30 status. P-
values were corrected for multiple testing using the Benjamini-Hochberg method. 
Significant skews were defined at a false-discovery rate of 1%.  
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2.31 Survival analyses. 
For purposes of modelling, clinical stages were aggregated into distinct groups (for 
instance, Stage IA and IB were grouped into Stage I). For selection of potential stratifiers 
or covariates for inclusion in Cox models, we first used Cox regression to estimate the 
strength of associations between age of diagnosis, year of diagnosis, grade and 
aggregated stage.  
Aggregated stage was the only significant covariate and was included as a 
covariate/stratifier in survival analyses.  Stratified, additive and interactive Cox 
proportional models and where applicable, checked the model of no interaction was 
justified using ANOVA, for F30 status, Clade and Type as predictors (one at a time with 
aggregate stage as a covariate). The analysis was also repeated by restricting tumours to 
early stage (Stages I and II). The appropriateness of proportional hazards assumptions 
was tested using the cox.zph function.    
2.32 Gene expression modelling of HPV type heterogeneity. 
Cox regression modelling indicated significant differences in survival between HPV45 
and HPV16, especially amongst early stage samples, with HPV18+ tumours comprising 
an intermediate group. To explore the extent and significance of molecular 
heterogeneity associated with HPV type comparisons were therefore performed 
between HPV16 and HPV45 + tumours.  
RNA seq RSEM fractional counts were quantile normalised and filtered to remove low-
expressed genes (less than 1 count per million in more than a quarter of samples). 
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Limma voom was then used to estimate mean-variance precision weights for robust 
linear modelling. Differentially expressed genes were identified at a mean fold-change of 
2 and a BH-corrected false-discovery rate of 0.01. 
2.33 Methylation modelling 
Differentially methylated probes were identified using a custom R wrapper to limma 
with correction for mean-variance trend upon empirical bayes modelling to account for 
the heteroscedasticity of beta-values. Significant MVPs were defined at a mean delta-
beta of 0.1 at a two-step BH adjusted false discovery rate of 0.01. Small beta-value 
thresholds were used to permit more sensitive detection of methylation differences.  
The identification of DMRs was carried out using fDMR, and DMRs were required to 
have at least 3 mvp's at a false discovery rate of 5% and an average deltaBeta difference 
of 0.1 and a DMR FDR of 0.05. Both these signatures were reduced to features 
associated with differential expression at an FDR of 0.01 and a fold change of 2, 
following limma-trend (Law, Chen et al. 2014) analysis of log2-cpm matrices reduced to 
genes in the signatures.   
2.34 Ingenuity Pathway Analysis 
A core analysis was carried out across the expression of genes from the whole-
transcriptome, DMR-associated and mvp-associated signatures by limiting interactions 
to experimentally validated ones. Canonical pathways analysis was adjusted for multiple 
testing during pathway selection.  
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Upstream regulatory networks were built using molecules with inferred states of 
activation/repression while controlling the p.value of overlaps for false discovery rate 
using the Benjamini-Hochberg method. False discovery rate correction was also carried 
out for any enrichment analyses involving multiple comparisons using custom R code 
written to analyse output of IPA analyses.  
2.35 Cohort-wide clustering analyses using HPV45-associated signature  
Joint clustering of the HPV45-16 gene expression signature and the functional MVP 
signature was carried out using a random forest proximity matrix to serve as the 
distance matrix across the dataset of stage I and stage II tumours. PAM Consensus 
Clustering was then carried out with 2:4 candidate clusters to identify the most robust 
partitioning of samples using a custom R wrapper calling clustering and robustness 
evaluation functions from the clusterCons R package.  
2.36 Survival Analyses of signature-derived clusters 
Cox proportional hazards regression was carried out for early stage samples across the 
cohort of HPV16+, HPV18+ and HPV45+ in two conditions; Firstly, all HPV45-like tumours 
versus all HPV16-like tumours, and secondly, all HPV45-like and HPV16-like tumours with 
HPV45s excluded in order to estimate utility beyond HPV45+ tumours. Independent 
contribution from these signatures was quantified by fitting Cox regression models with 
HPV type as a covariate in addition to aggregated clinical stage.  
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2.37 Development of a methylation biomarker.  
Linear-modelling was carried out to identify probes differentially methylated between 
HPV16-like and HPV45-like tumour clusters at an FDR of 0.01 (Two-step BH corrected), 
dB > 0.3. Significant MVPs were then used to train an assortment of classifiers with the 
following tuning parameters (Table 4) using the caret R package using 10 iterations of 10 
fold Cross-Validation. 
Model Parameters and Ranges 
K Nearest Neighbours (kNN) K (number of nearest neighbours) – 1,3,5 
Gradient Boosted Machine (gbm) Shrinkage – 0.01,0.1,0.5,1 ; Minimum observations in node = 
10, interaction depth – 5,10 , number of trees –  150,300 
Nearest Shrunken Centroid Threshold – 0.01,0.1,1,3,5,10,20. 
Glmnet (Elastic Net) Alpha – 0,0.2,0.4,0.6,0.8,1  ; Lambda – 0, 0.01, 0.02, 0.03, 
0.04, 0.05 
SVM (Support Vector Machine) – 
Linear Kernel (svmLinear) 
C – 0 to 1, intervals of 0.1.  
Random Forest mtry = 1/3 the number of features.  
Table 4: Machine Learning Models and Tuning Parameters for developing a model to 
classify cervical cancers into aggressiveness clusters. 
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For each model, the best parameters were selected on the basis of maximum Kappa 
values from the cross-validation tuning/fitting process. Class allocation for the dataset 
was made using out-of-fold calls to generate a majority vote. The different models were 
compared on the basis of Kappa values and how closely they recapitulated the Hazard 
Ratios of Cox regressions carried out on type-associated clusters to select a model for 
application to validation datasets.     
2.38 Development of a methylation signature for in-silico deconvolution.  
Dataset Assembly and Preprocessing 
Raw data were obtained in the form of IDAT files from a collection of sources that are 
summarised in (Table 5).CD4+ cells were removed from the Blood.450k dataset and 
CD4+ T-cells from the Chen dataset were binned into categories based on whether they 
were Tregs (T-regulatory cells) or not. Neutrophils are a subset of Granulocytes and 
therefore they were aggregated into a single category for further analysis. 
The files were parsed into R using the minfi Bioconductor package and were between-
array normalised using Functional Normalisation as implemented in minfi. Probe-type 
bias was corrected using BMIQ Normalisation with 10,000 reference probes and type2 
probes were also adjusted using Expectation-Maximisation fits.  
Derivation of signature features 
A custom limma based wrapper function was used to fit a series of linear models for one 
versus all other samples for each cell type. Features from this set of analyses were then 
restricted to MVPs that showed a median beta-value difference of 0.3 at an FDR of 0.01 
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for that fit or less. An additional filter was then applied based on whether probes 
associated with a cell type were hypermethylated or hypomethylated by a median beta-
value difference of at least 0.1 compared to the closest cell type in terms of median 
value for that probe.  
Cell Types Data Source Publication Reference/ Accession 
IDs 
Granulocytes (12), CD8+ (6), 
CD19 (6), CD56 (6), CD14 (6), 
Eosinophils (6) 
Blood.450k Bioconductor 
package.  
(Reinius, Acevedo et al. 2012) 
Fibroblasts (4) Gene Expression Omnibus GSE74977 
HNSC Cell Lines (12) , HeLa HNSC Cell Line Data from 
Matthias Lechner. HeLa 
from ENCODE 
HNSC Cell Lines: (Lechner, Fenton 
et al. 2013)HeLa : GSM999337 
CD4+ helper cells (6) and 
CD4+ Tregs (4) 
Raw data obtained 
through personal 
communication with Alicia 
Oshlack  
(Chen, Miao et al. 2015) 
Table 5: Datasets used to define cell-type specific signatures for MethylCIBERSORT 
deconvolution 
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Features were then ordered by t-statistics and the top and bottom 50 features were 
picked to try and ensure a balanced sampling of hypermethylated and hypomethylated 
probes.   Finally, for use with CIBERSORT, data were transformed from beta values 
(bound between 0 and 1) to percentages (0 – 100). Type-wise means were estimated for 
each probe and cell type and the matrix was exported for upload to CIBERSORT.  
2.39 Running Deconvolution Experiments using CIBERSORT 
The 844 methylome dataset, and the signature matrix derived in the previous step, were 
uploaded to CIBERSORT at https://cibersort.stanford.edu . The data were quantile 
normalised and CIBERSORT was run using 1000 permutations. Output files were 
downloaded as tab-delimited text files and custom parsers were used to import results 
into R for downstream analysis.  
2.40 Estimating accuracy of MethylCIBERSORT  
In the absence of flow-cytometry based estimates for the different cell types in the 
analysed tumours, the estimated fraction of Cancer Cells from MethylCIBERSORT was 
compared to sequencing-data based estimates from ABSOLUTE available for 466 HNSCs 
from previously published work (Aran, Sirota et al. 2015) using Spearman’s Rank 
Correlation. Additional correlations were investigated between ABSOLUTE and other 
methods of estimating purity/immune cell fraction in this subset of tumours – including 
LUMP, ESTIMATE and H&E staining assessment. Spearman’s Rank Correlation was used 
to estimate expression between marker transcripts (CD19 for B-cells, FOXP3 for Tregs, 
CD8 for CD8+ lymphocytes). Where applicable, multiple testing correction was 
performed using the Benjamini Hochberg approach.  
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2.41 Analysis of Immune Cell Fractions based on Cervical Cancer Aggressiveness 
Clusters 
The SVM trained on Cervical Cancers to classify samples into HPV45-like and HPV16-like 
samples was applied to the entirety of the 844 sample discovery set used for defining 
the Pan-tissue methylome signature for HPV-driven tumourigenesis using the “predict” 
function from the caret package. Immune cell fraction distributions were compared 
between the two allocated classes using Wilcoxon’s Rank Sum Tests. Multiple testing 
correction was carried out using Benjamini-Hochberg adjustment.  
2.42 Integrative Clustering and Enrichment/Overlap Analyses.  
Feature by Sample matrices were generated for 345 HPV+ samples with methylation 
data available consisting of Immune Cell Fraction estimates for seven immune cell types 
and stromal fibroblasts, and sets of immune effector molecules and immune 
checkpoints as defined in section 2.9. A Random Forest was then used to jointly estimate 
a Sample proximity matrix that was transformed into a dissimilarity measure using 
square root of 1-Proximity, and was divided into clusters using PAM clustering through a 
custom wrapper calling functions from the clusterCons package, as described earlier, 
with the most robust number of clusters from the range of two to five clusters picked as 
estimated using the clRob function. Overlap analyses were carried out using Fisher’s 
Exact Test.  
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2.43 Omic-Signatures for Immune Clusters 
Limma-trend was used to model differential expression between Immune-related 
clusters, and DEGs were called at 2FC, FDR < 0.01. Core Pathway Analysis was carried out 
using Ingenuity Pathway Analysis with experimentally confirmed direct interactions in 
human tissues/cells serving as the reference point. MVPs were defined between the two 
clusters at a median delta-Beta of 0.15 and a TSBH FDR < 0.01 and were then reduced to 
cfMVPs based on concordant overlaps with DEGs.  
RPPA protein data were obtained for 162 samples for 194 proteins from the UCSC 
Cancer Browser, quantile normalised, and then differential antibody staining was 
estimated using limma-trend as for expression, with a cutoff of FDR < 0.05.  
2.44 Survival Analyses of Immune Clusters  
Clinical data were downloaded from the UCSC Cancer Browser for 337 of the 356 HPV+ 
samples for which immune cluster, aggressiveness cluster and cellular infiltration 
estimates were available. Cox proportional hazards regression was used to estimate the 
impact of immune cell fractions (Percentages from MethylCIBERSORT analysis) on 
survival. The following models were evaluated… 
A) Multivariate Cox regression to estimate impact of Immune cluster, with strata for 
stage and age at diagnosis as covariates.  
B) Cox regression models fit separately in Head and Neck Cancer and Cervical Cancer 
with age at diagnosis and stage as covariates and all infiltrating cell type estimates set as 
predictors. HR estimates were derived per percent increase in cell fraction.  
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C) A threshold based model where estimates were split into four quartiles and 
comparisons were carried out between upper and lower quartiles, with age and stage 
for covariates. Models were fit separately for Head and Neck and Cervix.  
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Chapter 3: HPV-driven 
transformation is marked by a 
conserved pan-tissue signature of 
transcriptional dysregulation. 
I published many of the findings in this chapter in the Journal of Clinical Oncology, with 
the paper titled “Human Papillomavirus Drives Tumor Development Throughout the 
Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely 
Restricted to the Oropharynx.” (Chakravarthy, Henderson et al. 2016). The main 
analytical steps and the relationship between datasets are described in a flowchart in 
Appendix A3. The clinical data used for comparing HPV+ OPSCC and Non-OPSCC are 
summarised in Appendix A4.  
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Meta-analysis identifies a 179 feature signature of HPV-associated 
transcriptional changes. 
I conducted a meta-analysis of 7 gene expression microarray studies that included tissue 
samples and cell line models representing normal epithelium (69), HPV- (55) and HPV+ 
(138) tumours (Table 2: See Methods, page 48). 179 probes, representing 159 unique 
genes, were differentially expressed in the HPV+ samples according to stringent criteria 
for statistical significance (FDR <0.01) and fold change in expression (FC >2) (hereby, this 
gene set is referred to as the metasignature).  This was done to estimate the significance 
of genes to derive a pan-tissue HPV-associated signature while reducing the influence of 
platform and study-specific effects that could confound joint analysis.  
This gene signature showed a consistent pattern of differential expression between 
HPV+ tumours and HPV- tumours or normal tissue across the clinical sample datasets 
used in the study as visualized using heatmaps (Figure 3), exhibiting general clustering. 
Visualisation of signature gene expression in a published dataset consisting of 
keratinocytes transformed with HPV16 (Kravchenko-Balasha, Mizrachy-Schwartz et al. 
2009) revealed stronger expression in late passage and benzopyrene treated late-
passage transformed keratinocytes than that of cells profiled immediately following HPV 
infection, resulting in accurate clustering (Figure 4).  
These data suggest that the expression signature reflects the action of HPV in concert 
with cellular changes that occur during transformation, rather than simply a set of genes 
directly modulated by HPV. 
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Figure 3: Heatmapping reveals expression differences between HPV+ samples and HPV- 
controls across tissue and cancer types. Clustering generally occurs by HPV status. In 
annotation ribbons, top row represents HPV status, bottom row represents sample type. 
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Figure 4: Meta-Signature genes show maximal expression in late-passage and benzopyrene-
treated late passage foreskin keratinocytes transformed with HPV relative to HPV- controls 
and early passage HPV+ cells. 
 
The expression of HPV-signature genes is modulated by the 
expression of E6/E7 in concert with additional oncogenic hits.  
To further investigate the influence of HPV oncogene expression and additional 
alterations in cellular genes on expression of the signature analysis was carried out on  
an expression dataset derived from the stepwise transformation of mesenchymal stem 
cells (MSCs): unmodified MSCs; MSCs+hTert; MSCs+hTERT+E6/E7; 
MSCs+hTERT+E6/E7+SV40 small T,  MSCs+hTERT+HPV16 E6/E7+SV40 small T+HRAS V12  
(Funes, Quintero et al. 2007).  Cluster multiscale bootstrap analysis (Figure 5A)  showed 
the presence of three robust clusters based on expression of the HPV signature. 
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These clusters corresponded to: (1) primary and hTERT-immortalized MSCs; (2) 
immortalized MSCs expressing HPV16 E7 (with or without E6) and (3) E6/E7 expressing 
MSCs expressing additional oncogenes (SV40 small T and mutant HRAS). The expression 
of the HPV-associated signature is most closely recapitulated in cluster 3 (Figure 6), i.e. 
cells that are expressing not only the HPV oncogenes but also the SV40 small T antigen 
(with or without the addition of oncogenic HRAS). SV40 small T inhibits the PP2A 
phosphatase and its primary target in transformation appears to be the stabilization of 
c-MYC (Yeh, Cunningham et al. 2004).  
These findings from both the keratinocyte and MSC transformation models suggest not 
surprisingly, that the megasignature for HPV-driven tumours results from the combined 
action of the HPV oncogenes and the activation of cellular proto-oncogenes that are 
known to be important for full transformation. Additionally, the fact that the signature is 
recapitulated upon transformation of mesenchymal stem cells demonstrates that many 
of these genes are modulated during HPV-driven transformation, independent not only 
of the anatomical site or tissue of origin but also of the cellular lineage involved. Indeed, 
the intensity of signature gene expression also increases with degree of transformation 
in E-GEOD-7803 from CIN3 to cancer (Figure  3). 
The presence of a distinct robust cluster consisting of E6/E7 positive tMSCs with 
additional oncogenic hits with the metasignature that clusters away from E6/E7 
expressing cells alone and tMSCs but not upon clustering using features in a signature 
previously proposed by (Buitrago-Perez, Garaulet et al. 2009) (Figure 5B) suggests that 
the metasignature is a better approximation of full transformation in the presence of 
HPV than just E6/E7 expression.  
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Figure 5: A) Application of the meta-signature results in stratification of tMSCs into three 
robust clusters (top) by average linkage euclidean distance resampling whereas a previously 
defined signature (B) does not (bottom). Red boxes define clusters with bootstrap stability 
> 0.95. E6/E7 + oncogene transformed cells represent fully transformed cells. 
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Figure 6:The HPV meta-signature is best recapitulated in cells containing E6/E7 and 
additional oncogenes. Intensities represent row z-scores 
 
 
Canonical Pathway Analysis implicates pathways associated with 
the known biology of HPV positive cancers.  
By deriving a list of genes whose expression becomes deregulated in HPV-driven 
cancers, irrespective of the anatomical site at which they occur, I aimed to identify a 
core set of pathways that are important for the development and maintenance of these 
tumours.  
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To determine the major pathways represented and enriched in the HPV-expression 
signature I performed canonical pathway analysis using the Ingenuity Pathway Analysis 
(IPA) software (see methods). Canonical pathway analysis of the signature genes 
identified multiple pathways associated with cell cycle progression, as previously noted 
by (Pyeon, Newton et al. 2007, Buitrago-Perez, Garaulet et al. 2009),DNA damage and 
DNA replication as significantly enriched amongst signature genes (Appendix A1).  
The mechanisms by which HPV promotes cell cycle entry and DNA replication have been 
intensively studied, lending to confidence in the procedure used to derive the signature 
by relating a number of signature genes and pathways to well-established facets of HPV 
biology.  
Firstly, the abrogation of pRb function by E7 overcomes the need for CyclinD1-Cdk4/6 
activity to drive passage through the G1/S transition and commitment to DNA 
replication. Consistent with this, the metasignature is characterised by reduced CCND1 
expression and upregulation of CCNE2 & CDK1, which act at later stages of the cell cycle 
(Figure 7). 
Consistent with HPV biology is the status of CDKN2A as a signature gene. While CDKN2A 
is frequently lost or mutated in HPV-negative tumours, it is induced in cells expressing E7 
and the protein product p16INK4A is used as a biomarker for HPV+ tumours (Klaes, 
Friedrich et al. 2001). CDKN2A, in addition to being a biomarker for HPV-transformed 
cells, also appears to be necessary for their survival through its role in suppressing an as-
yet uncharacterized CDK4/6-dependent cell death pathway (McLaughlin-Drubin, Park et 
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Figure 7: Cell Cycle Progression is remodelled in HPV+ tumours, with progression mainly 
mediated by CCNE-CDK1 complexes as opposed to CCND1-CDK4/6 complexes, which is 
reflected in the relative downregulation of CCND1. The tumour suppressor CDKN2A, SCF, 
and CCNB1 are also strongly upregulated. Overexpressed genes are in red, underexpressed 
genes are in blue, and HPV oncoprotein targets (E6 and E7) are coloured in orange.  
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Multiple genes required for DNA replication and S-phase progression are represented in 
the signature, including all six MCM complex members (MCM2-7), TIMELESS, the 
replication factor C subunits RFC4 and 5 and RPA2. The upregulation of these genes may 
reflect the replication stress caused caused by aberrant S-phase entry in cells expressing 
HPV oncogenes. The single stranded (ss)DNA-binding protein, RPA2 and another 
signature gene product, FANCI have both been implicated in promoting DNA repair at 
stalled or collapsed replication forks, a process impacted by E6 (Smogorzewska, 
Matsuoka et al. 2007, Day and Vaziri 2009, Shi, Feng et al. 2010) as well as CCNE 
overexpression (Ekholm-Reed, Mendez et al. 2004). Furthermore, FANCI is a component 
of the Fanconi Anaemia complex, which is activated in response to DNA damage caused 
by E7 expression (Spardy, Duensing et al. 2007, Park, Shin et al. 2013).  
TIMELESS plays a key role in relaying the replication stress checkpoint signal from ATR to 
Chk1 while RFC4 and 5 play dual roles in DNA replication and repair, including loading of 
the 9-1-1 complex onto DNA in response to replication stress (Unsal-Kacmaz, Mullen et 
al. 2005, Mailand, Gibbs-Seymour et al. 2013).  
Upstream regulator analysis identifies known and novel candidate 
upstream regulators associated with HPV oncoprotein function. 
In addition to investigating the biological pathways in which metasignature genes 
participate, I also used IPA upstream regulator analysis to identify the major pathways 
whose modulation in HPV+ cancers induces these expression patterns.   
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Figure 8: Network of upstream regulators inferred from the  metasignature using Ingenuity 
Pathway Analysis. Blue = inferred inhibition , Orange = inferred activation , Red and Green 
represent overexpressed and underexpressed genes in HPV+ tumours respectively, ,Solid 
Line = direct relationships , Dashed Line = indirect relationships, Orange Line = inferred 
state of upstream regulator is consistent with expression state of effector genes, Yellow 
Line = inferred state of upstream regulator inconsistent with expression state of effector 
genes (Appendix A2). 
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As expected, two of the significantly inhibited upstream regulators are TP53, which is 
the primary target of E6, and ATF3, which has been implicated as an activator of TP53 by 
blocking E6-mediated degradation through antagonistic interactions with E6AP (Wang, 
Mo et al. 2010)(Figure 8). 
Interestingly, the signature is suggestive of impaired transcriptional influence of p53 that 
is caused by its depletion by E6 as opposed to the gain of aberrant transcription in 
tumours that acquire gain-of-function mutations in TP53 (Brosh and Rotter 2009). TP53 
mutations are a prominent feature of HPV- HNSCs (Perez-Ordonez, Beauchemin et al. 
2006, Stransky, Egloff et al. 2011, Lechner, Frampton et al. 2013), thus the signature may 
reflect different mechanisms of p53 dysregulation in HPV+ and HPV- tumours. Other 
dysregulated upstream regulators, as expected from prior discoveries on HPV 
oncoprotein function, include the inferred activation of E2F3, which is amongst the 
transcription factors in the E2F family repressed by Rb and the inhibition of E2F6, which 
is known to be bound by HPV16 E7. (McLaughlin-Drubin, Huh et al. 2008) 
In addition to these expected regulators, I also identified several potential regulatory 
genes not previously implicated in HPV biology, including KDM5b, FOXO, FOXM1 and 
NUPR1. KDM5B, a demethylase responsible for the repression of transcription through 
removal of trimethyl marks from lysine 4 of histone H3 was identified as being a 
significantly inhibited upstream regulator. KDM5B has been shown to act in association 
with pRb in the repression of E2F target genes, thus the inferred downregulation of 
KDM5B function in HPV+ cancers may be a consequence of pRb targeting by 
E7(Nijwening, Geutjes et al. 2011).  
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Other significantly dysregulated upstream regulators in HPV+ tumours include NUPR1, 
whose function is also inhibited in the HPV+ tumours. This is a multifunctional protein 
involved in response to cellular stress that has been implicated in chemoresistance to 
taxols and doxorubicin through the upregulation of p21 and antiapoptotic Bcl-x(L) (Clark, 
Mitra et al. 2008, Chowdhury, Samant et al. 2009).  
FOXM1 was another upstream regulator that was inferred to be activated and this is 
consistent with its role in modulating the activation of E2F-target genes as part of the 
DP1-pRb family-E2F DREAM complex in combination with HPVE7 during during G2-M 
progression (DeCaprio 2014).   
Epigenetic modifiers are represented in the metasignature and are 
putative therapeutic targets.  
The epigenetic regulators in the signature include ACTL6a, HTLF and LSH, all chromatin 
remodellers associated with the SWI/SNF complex, in addition to the histone 
demethylase EZH2 which has been previously implicated in HPV-driven cancers 
(Buitrago-Perez, Garaulet et al. 2009). ACTL6a has been implicated as a master regulator 
of stemness in epidermal keratinocytes (Bao, Tang et al. 2013) and has been shown to 
be necessary for E6/E7 transcription in CESC cell lines (Lee, Lee et al. 2011) while HELLS 
has been shown to drive E2F3 (inferred to be activated based on the metasignature) 
mediated transcriptional programmes (von Eyss, Maaskola et al. 2012); consequently, 
the metasignature  includes multiple novel chromatin remodellers subject to 
dysregulation in HPV-driven tumours that may be amenable to therapeutic targeting.   
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Validation of the meta-signature reveals reliable classification 
performance. 
In order to test the performance of the metasignature in an independent dataset, I used 
RNA-seq profiles for HNSC performed by TCGA. The meta-signature was compared to 10 
random sets of 157 features not in the signature and to two other previously published 
signatures using Kappa as the accuracy metric across 10 iterations of 10 fold Cross-
Validation.  
 
Figure 9: Comparison of Out-of-fold Kappa Values in the TCGA HNSC dataset between the 
MetaSignature, models trained on 10 random sets of non-metasignature features, and 
previously published signatures. X-axis = Kappa values, Y-axis = Model. 
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The signature performed significantly better than the random sets (p-value < 2.2e-16, 
Wilcoxon's Rank Sum Test) and comparably to a signature derived using list comparison 
and from supervised analysis from the validation dataset previously reported (Figure 9) .  
Notably, the metasignature contained new genes not previously implicated as being 
transcriptionally dysregulated in HPV driven cancers.  Visualising the expression of 
Metasignature genes in the TCGA cohort indicated highly accurate clustering by HPV 
status (Figure 10). HPV+ tumours appeared to be correctly classified even if non-
Oropharyngeal, leading to further analyses of subsite specific differences.  
A large subset of the Metasignature is uniquely dysregulated in 
HPV+ tumours.  
Having established using the TCGA HNSC cohort that the metasignature is differentially 
expressed between HPV+ HNSCs, HPV- HNSCs/Normal tissue, I tested if these patterns 
were unique to HPV+ tumours when considered relative to a broad range of other 
tumour types arising in a variety of tissues. Using a collection of 13 other tumour types 
(minimum 5 normal samples) and linear modelling in addition to HNSCs, testing for 
differential expression of metasignature genes between HPV+ and HPV- tumours after 
controlling for anatomic site and Cancer/Normal status revealed 80/157 genes to be 
differentially expressed at 2FC, FDR < 0.01, suggesting many of these transcriptional 
changes are unique to HPV+ tumours.  
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Figure 10: Heatmap of metasignature genes in the TCGA HNSC dataset (n = 561). Samples 
in columns and expression Z-scores in rows. Annotation rows from top to bottom indicate 
Random Forest predictions, HPV status by RNA-transcripts, anatomical subsite and 
Cancer/Normal status. Neg = HPV- , Pos= HPV+ , Oro = Oropharyngeal, NonOro = Non-
Oropharyngeal, Norm = Normal. 
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HPV transcript-positive OPSCC and non-OPSCC share common 
transcriptomic/methylomic patterns. 
The hypothesis that HPV+ non-OPSCCs share HPV-associated molecular profiles with 
HPV+ OPSCCs was tested on RNA-sequenced HNSC from the TCGA (n=520, 54 HPV+ 
OPSCC, 21 HPV+ Non-OPSCC, 26 HPV- OPSCC, 419 HPV- non-OPSCC) using the Random 
Forest classifier trained on the expression signature as described earlier in this chapter 
and also one trained on a signature of Methylation Variable Positions (MVPs) different 
between HPV+ and HPV- OPSCC.  
Heatmapping revealed that in both cases (Figure 11), HPV+ tumours tended to cluster 
together into one or two distinct clusters, with OPSCC and non-OPSCC samples 
interspersed. Analyses of classification using aggregated out-of-fold predictions from 
Random Forests showed robust classification performance and the appropriate 
classification of the vast majority of samples, with 71/75 HPV+ tumours correctly 
classified by the Expression-based classifier (Kappa = 0.96) and 61/68 HPV+ tumours 
correctly classified by the Methylation classifier (Kappa = 0.92).  
Having demonstrated that transcriptional and epigenomic patterns are conserved 
between HPV+ OPSCCs and Non-OPSCCs, expression patterns of the primary viral 
oncogenes E6 and E7 were compared by anatomical subsite. Overall distributions for 
both E6 and E7 were similar and no significant differences in distributions were 
identified (Wilcoxon’s Rank Sum Test) (Figure 12).  
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Figure 11: Visualisation of HPV-associated molecular signatures in the TCGA HNSC cohort. 
A) Expression metasignature (n=520), B) MVPs associated with HPV+ OPSCC (Oro) relative 
to HPV- OPSCC are also preserved in HPV+ non-OPSCC (non-Oro) . Annotation bars show 
Random Forest predictions, HPV transcript status and anatomic subsite. Samples in columns 
and features in rows, with Z-scores represented for expression data and beta-values for 
methylation.11A is reproduced from Figure 10 for convenience.  
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Figure 12: Distributions of HPV E6 and E7 expression are similar between HPV+ OPSCC and 
non-OPSCC for HPV types found in both subsites. 
 
Genomic analyses further support an aetiological role for HPV 
outside the Oropharynx. 
Having observed strong similarities between HPV+ tumours from oropharyngeal and 
non-oropharyngeal sites at the gene expression and epigenetic levels, I investigated if 
large-scale genomic similarities existed by subsite.  
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Previous work has revealed that HPV- and HPV+ OPSCCs display characteristic mutations 
and/or copy number alterations (CNAs). In particular, alterations to TP53, CDKN2A and 
CCND1 are almost exclusive to HPV-negative OPSCC, in which they occur at high 
frequency ((Gillison, Chaturvedi et al. 2015), (van Houten, Snijders et al. 2001), (Lechner, 
Frampton et al. 2013), (TCGA 2015)). In HPV-driven OPSCC and cervical cancer, it is 
thought that E6-mediated p53 degradation removes the selection pressure for TP53 
gene mutations and that bypass of the G1/S checkpoint by E7 likewise obviates the 
pressure to acquire CDKN2A or CCND1 alterations (Westra, Taube et al. 2008, Lechner, 
Frampton et al. 2013). 
 
 
 
Group 
 
 
TP53 mutations 
 
 
 
CDKN2A mutations 
 
 
CCND1 Amplification 
 
CDKN2A 
Deletions 
(Deep + Shallow 
Deletion)  
 
HPV + OPSCC 
 
 
0/50 (0%) 
 
0/50 (0%) 
 
 
6/54 (11.1%) 
3 + 1 /54    
(7.4%) 
 
HPV+ Non-OPSCC 
 
 
1/18 (5.5%) 
 
0/18 (0%) 
 
3/21 (14.2%) 
1 + 2/21 
(14.2%) 
 
HPV- OPSCC 
 
 
23/25 (92%) 
 
5/25 (20%) 
 
19/26 (73.7%) 
10+12/26 
(84%) 
 
HPV- Non-OPSCC 
 
 
336/409 (82%) 
 
107/409 (26%) 
 
197/413 (47.6%) 
140+141/413 
(68%) 
Table 6: Breakdown of Hallmark genomic alterations in CDKN2A, TP53 and CCND1. HPV+ 
OPSCC and Non-OPSCC display similar frequencies of alteration. 
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As expected, high frequencies of TP53 mutations, CDKN2A mutations, CDKN2A deletions 
and CCND1 amplifications were evident in both HPV- OPSCC and non-OPSCC but not in 
HPV+ OPSCC.  The HPV+ non-OPSCC tumours resembled the HPV+ OPSCCs (Table 6). 
Taken together, these genomic analyses further buttress the characterisation of HPV as 
a driver in transcript-positive non-OPSCC. 
Of the 3 HPV+ tumours that were misclassified as HPV- on the basis of both the 
transcriptional and epigenetic signatures, two displayed low viral transcript counts of 
125 and 5908 viral reads (overall mean=35204; range 125-202666), one had a CCND1 
amplification and a CDKN2A deletion (much more common in HPV- disease) and one 
contained an atypical HPV-type that was a singleton in the dataset (HPV56). This 
suggests that even the presence of HPV RNA may occasionally lead to erroneous 
conclusions about aetiology - highlighting the importance of an integrated molecular 
approach to identifying the HPV status of these tumours. The 3 misclassified samples 
were removed for further analysis. 
HPV+ HNSC may show subsite-associated prognostic differences. 
Large clinical trials have established that HPV+ OPSCC patients have markedly better 
clinical outcomes compared to HPV- OPSCC (Fakhry, Westra et al. 2008, Ang, Harris et al. 
2010) . These findings have led to de-escalation trials aimed at reducing the treatment 
associated morbidity seen with chemoradiation when Oropharyngeal cancers are HPV-
driven (reviewed in (Vokes, Agrawal et al. 2015)). The discovery that molecular profiles 
are conserved between HPV+ OPSCC and non-OPSCC raises questions of clinical 
behaviour and management in the latter.  
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To date, two previous studies have investigated the relationship between p16 
overexpression, (a proven biomarker for HPV status in OPSCC) and outcome in non-
OPSCCs.  One reported no survival benefit associated with p16 expression outside the 
oropharynx (Lassen, Primdahl et al. 2014) but did so in OPSCC, whereas analyses from 
another trial showed that p16-overexpressing tumours were associated with better 
outcomes regardless of anatomical subsite, but did not demonstrate benefits associated 
with HPV DNA positivity in non-OPSCCs (Chung, Zhang et al. 2014).  
 
 
Figure 13: Overall Survival in the TCGA HNSC cohort, stratified by HPV status and anatomic 
subsite. HPV+ OPSCC was associated with significantly better survival than HPV+ non-
OPSCC. P-value and Hazard Ratio from multivariate Cox regression. X-axis = time in days, 
Y-axis = survival probability. The table indicates number of patients at risk of death.  
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Kaplan-Meier curves (Figure 13) showed that HPV+ OPSCC and HPV+ non-OPSCC may be 
associated with different clinical trajectories (HR = 0.17, p = 0.05, CI = 0.03 – 0.99). This 
led me to consider various factors to explain this prognostic gap by subsite.  
 Firstly, comparisons were carried out of the transcriptomes of HPV+ OPSCC vs HPV+ 
Non-OPSCC, leading to the identification of 68 DEGs (FDR < 0.01, 2FC). Pathway analyses 
of this gene set identified “migration of cells” as the most enriched process in the HPV+ 
non-OPSCC tumours (Activation z-score = 2.69, p = 2.46E-03) attesting to an additional 
layer of transcriptional dysregulation as one putative reason for survival differences by 
anatomic subsite in HPV+ HNSC. Comparisons of methylation data showed no MVPs 
significantly different (delta-Beta > 0.4, FDR < 0.01). Moreover, almost universal 
retention of wild-type TP53 (previously linked to increased radiosensitivity in HPV+ 
OPSCC (Kimple, Smith et al. 2013)) in HPV+ non-OPSCC (Table 1) was observed, 
suggesting an alternative explanation for the survival difference by subsite within HPV+ 
tumours. 
Anatomic subsite is associated with differences in TIL levels and 
activity 
Reviewing the literature surrounding determinants of outcome in HPV+ tumours, 
revealed that levels of tumour-infiltrating lymphocytes (TILs) are correlated with 
outcome in HPV+ OPSCC, with low TIL numbers designating a poor-prognosis group of 
HPV+ patients whose survival did not differ from patients with HPV- OPSCCs (Ward, 
Thirdborough et al. 2014). Immune infiltration has also been described as a prognostic 
stratifier in HPV-associated anal cancer (Gilbert, Serup-Hansen et al. 2016).  
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The importance of the immune system in shaping the evolution of HPV+ OPSCC is also 
reflected by HPV+ OPSCC cells frequently expressing high levels of the immune 
checkpoint ligand PD-L1 to evade immune destruction (Lyford-Pike, Peng et al. 2013). 
The fact that the tonsils and base of tongue are lymphoid tissues, and that high TIL levels 
are a common feature of these tumours led to the hypothesis that TIL levels in OPSCCs 
are higher than those found in non-OPSCCs, allowing a potent therapy-primed immune 
response in the Oropharyngeal setting and potentially explaining the difference in 
outcome.   
This hypothesis was tested using two measures of infiltrating lymphocytes: firstly, the 
measurement of CD4 (Helper / Regulatory T lymphocyte), CD8A/CD8B (Cytotoxic T 
lymphocyte) RNA transcript abundance (VST) as surrogates for immune infiltrate activity 
led to the discovery of significantly higher levels of these infiltrating lymphocyte markers 
in HPV+ OPSCCs (All at FDR < 0.05) (Figure 14A).  
This analysis was complemented by pathological evaluation of images from H&E stained 
sections (available from the TCGA Digital Image Archive) by a pathologist (Prof Gareth 
Thomas, University of Southampton, a collaborator), who was blinded to anatomic 
subsite. Statistical analysis of his histopathological estimates suggested increased TILs in 
HPV+ OPSCCs versus HPV+ non-OPSCCs (Figure 14B, Cochran-Armitage Trend Test, p = 
0.046).   
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Figure 14: A) Breakdown of TIL receptor expression (log2 counts per million) by 
combinations of HPV status and anatomical subsite. FDR from Wilcoxon's Rank Sum Test, 
HPV+ OPSCC vs Non-OPSCC. B) HPV+ OPSCC are more likely to be TIL-high relative to 
HPV+ Non-OPSCC as scored by a pathologist based on examination of H&E slide images 
from TCGA. P.Value from Cochran-Armitage test for trend. Pos and Neg represent HPV 
status and Oro and Non-Oro represent OPSCC and Non-OPSCC respectively in the figure. 
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Figure 15: mRNA expression (log2 counts per million) of TIL Effector Molecules. q-values 
from Wilcoxon's Rank Sum Tests between HPV+ OPSCC and HPV+ non-OPSCC. X axis 
represents groups by HPV status and anatomic subsite. Pos and Neg represent HPV status 
and Oro and Non-Oro represent OPSCC and Non-OPSCC respectively in the figure.  
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Figure 16: A) Clustering using a panel of immune cell markers, effector genes and immune 
checkpoint transcripts separates HPV+ HNSCs (Non-Oro = Non-OPSCC, Oro = OPSCC) into 
two distinct groups. B) These groups show differential survival. Stats from multivariate Cox 
regression. Y-axis – probability of survival, X-axis – time to most recent followup in days. 
Table indicates numbers of patients at risk. Also see Appendix A4 for all coefficients. 
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It was then tested if differences in TIL levels within these subgroups of tumours defined 
by HPV status and anatomic subsite was associated with differential TIL activity by 
evaluating the expression of the effector markers granzymes (Granzyme A,B,H,K and M), 
perforin, their upstream activator IL2 (Janas, Groves et al. 2005), and Interferon-gamma 
(Bold and Ernst 2012) expression.  
HPV+ OPSCC displayed elevated levels of a large subset of these markers relative to each 
of the other three groups (Figure 15) (FDR < 0.1 between HPV+ OPSCC and non-OPSCC). 
Finally, PAM consensus clustering was carried out using a panel of these markers, 
effectors and known immune-checkpoint molecules, derived by manual curation. This 
separated samples into two distinct clusters, marked by high and low expression of the 
transcripts in the panel respectively (Figure 16A).  The low expression cluster showed 
enrichment for HPV+ non-OPSCC (14/18) relative to HPV+ OPSCC (19/54) (p = 0.002, 
Fisher’s exact test) further reflective of low immune infiltrates. Immune cluster was then 
found to be significantly associated with outcome (immune cluster high vs low 
HR=0.1622, p=0.0431, CI=0.035-0.8595, Figure 16B) after controlling for anatomic 
subsite, T-stage, node stage and age at diagnosis (NB – these covariates have all been 
shown to be relevant within HPV+ OPSCC, see methods for dichotomisation criteria). 
Secondary validation based on clustering samples using four WGCNA (Weighted Gene 
Correlation Network Analysis)  modules previously associated with HPV+ tumours, some 
of which were also correlated with lymphocyte activity (Ottensmeier, Perry et al. 2016) 
also recapitulated similar associations with survival in multivariate analyses (HR = 0.21, p 
= 0.031, CI=0.05-0.86). These findings demonstrate that HPV+ OPSCCs are subject to 
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higher levels of TIL activity, and display an immunoactive transcriptional profile that is 
prognostically informative.   
Intriguingly, both of the gene sets used to define the clusters above show inexact 
correspondence with histopathological estimates of lymphocyte infiltration; using the 
immune activity panel I derived in this chapter, 7/18 High-TIL, 5/10 Moderate-TIL and 
16/20 low-TIL samples were associated with the low-expression cluster.  This indicates 
there may be samples with high levels of infiltration that nonetheless are not marked by 
effector function, or that there may be tumours with small numbers of infiltrating 
lymphocytes that may still be capable of potent anti-tumour responses, marked by 
distinct molecular profiles.  
Chapter Conclusions  
The work carried out in this chapter represents, to date, the most comprehensive 
assembly and analysis of transcriptomes from models and tumours transformed by HPV. 
Transcriptional patterns that mark HPV+ tumours are consistent with origins in the 
direct activity of HPV E6 and E7, which is evident in the induction of the signature in 
transformed Mesenchymal Stem Cells, with marked changes in expression patterns of 
genes that regulate cell cycle progression. Validation of the metasignature through 
machine learning and comparisons using RNA-seq data across a large panel of cancer 
types both indicate that the metasignature is capable of being a functional readout for 
the activity of HPV.  
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A large subset of the metasignature is perturbed in unique ways and to magnitudes not 
typical of many other tumour types and is of potential utility for developing 
transcriptional biomarkers to test for the active involvement of HPV in tumourigenesis.  
The confirmation of a driver role for HPV in non-OPSCC has multiple implications for 
clinical management of these tumours, firstly, the worse prognosis associated with these 
tumours suggests therapeutic de-escalation is ill-advised, and secondly, the generally 
immune-depleted pattern associated with these tumours suggests that HPV+ OPSCC 
patients may be more likely to respond to immune-checkpoint blockade relative to HPV+ 
non-OPSCC, while drugs that specifically target HPV-driven tumours may be useful 
regardless of subsite.  The immune activity transcriptional profiles derived in this 
chapter will facilitate the stratification of patients for immunotherapy.  
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Chapter 4: APOBEC-mediated 
mutagenesis is a key driver of 
genomic evolution in HPV+ cancers.  
Note – interim analyses of the work presented in this chapter were published as a paper 
(Henderson, Chakravarthy et al. 2014) involving collaborative software development and 
analyses with Stephen Henderson of the Bill Lyons Informatics Centre, UCL Cancer 
Institute. I received joint-lead authorship for my contribution to the interim analysis. I 
generated all new code where required and performed all the analyses on the extended 
dataset used in this chapter, while leveraging on the tools and ideas established and 
generated during the interim analysis.   
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Multiple genes in the gene expression signature suggest 
involvement of APOBEC-activity in mutagenesis and genomic 
evolution.  
One of the many metasignature genes that were also unique to HPV+ tumours across 
the pan-cancer cohort was APOBEC3B (Fold change 3.48), which encodes a cytidine 
deaminase enzyme responsible for editing of viral DNA during the innate immune 
response to infection. Mutations indicative of APOBEC editing have been reported in 
both HPV DNA isolated from cervical dysplasias and more recently in cellular DNA from 
HPV+ HNSC and CESC; presumably the result of an off-target activity that can be selected 
for during tumour development (Vartanian, Guetard et al. 2008, Burns, Temiz et al. 
2013, Roberts, Lawrence et al. 2013, Henderson, Chakravarthy et al. 2014).  
When expression was visualised across samples from the TCGA PanCan dataset for 
cancer types for which at least 5 normal samples were available, HPV+ HNSCs were 
found to have amongst the highest expression of APOBEC3B (Figure 17). APOBEC3B 
targets ssDNA, and it has been proposed that exposure of the ssDNA substrate, as occurs 
at stalled replication forks, rather than the level of APOBEC enzymes, is the key limiting 
factor for this mode of somatic mutagenesis (Roberts and Gordenin 2014).  
Findings presented in the previous chapter indicate that HPV+ tumour cells express 
multiple genes involved in the repair of DNA damaged during replication and together 
with the known ability of E6 and E7 to induce replication fork stalling, suggested that 
HPV-driven tumourigenesis might be associated with APOBEC-mediated mutagenesis.  
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Figure 17:Plot of APOBEC3B expression (log2 (cpm+0.5)) across tumour types with both 
normal and cancer samples available from the TCGA (minimum 5 normal samples). HPV+ 
HNSCs (red) exhibit some of the highest levels of APOBEC3B expression. 
 
APOBEC mediated mutagenesis is significantly enriched in HPV+ 
HNSC relative to HPV- HNSC.  
While previous reports indicated a very high level of APOBEC-induced mutations in 
cervical tumours, it was unclear if this was associated with HPV or with tissue of origin. 
HPV-association was therefore tested by comparing HPV+ and HPV- HNSCs.   
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Previously, four distinct mutational signatures that were defined across a broad cohort 
of cancer genomes and exomes were found to be operative in HNSC, with APOBEC 
implicated in generating two of these. Using a method to deconvolute spectra 
(Rosenthal, McGranahan et al. 2016) into signatures on a per-sample basis, the number 
of mutations mapping to these signatures and those that did not were estimated.  
 
 
Figure 18: A - GLM analysis reveals significant associations with HPV status for APOBEC 
signatures according to the proportion of mutations categorised as Alexandrov APOBEC 
mutations or supervised analysis using subclasses of TCW -> TKW mutations. B - calculating 
localised enrichment scores for APOBEC to non-APOBEC mutations reveals significant 
differences in the distributions of APOBEC-enrichment scores by HPV status in HNSCs.  
Fitting binomial generalised linear models to the proportion of mutations attributable to 
the Alexandrov APOBEC unsupervised signature (comprised of signatures 2 and 13 from 
(Alexandrov, Nik-Zainal et al. 2013), representing both C>T mutations that are associated 
with multiple processes and C>G mutations that are more APOBEC-specific) as well as 
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proportions of APOBEC mutations defined by supervised analysis using TCW to TKW 
mutation fraction as a determinant of APOBEC mediated mutagenesis, where K = T/G 
and W=A/T identified HPV status was a significant predictor of candidate APOBEC-
mediated mutations with a large effect size (OR range across models – 2.35 – 5.90) 
(Figure 18A) while age and smoking resulted in small and significant effects, which is not 
surprising since they are processes that contribute to mutational signatures that are 
non-APOBEC. 
These approaches were also validated by comparison to a localised enrichment score 
based on the likelihood of mutations based on the local sequence context of mutant 
bases and HPV+ tumours were again significantly enriched upon permutation testing of 
the difference in means (p=0.0045) (Figure 18B). In all cases, HPV status was a strong 
predictor of enrichment for APOBEC-mediated mutagenesis. 
APOBEC-mediated mutagenesis is not part of a generalised 
antiviral response. 
Given the role of APOBEC-mediated cytosine deamination in antiviral immunity, I then 
tested if other virally-driven tumours were similar to HPV+ tumours (194 CESC, 68 HPV+ 
HNSC) in displaying enrichment for this mutational process using HBV/HCV+ (Hepatitis B 
Virus/ Hepatitis C Virus) Hepatocellular carcinomas (HCC, n=213) and EBV+ Stomach  
Adenocarcinomas (STAD, n=26).  
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Figure 19: A) Sequence logos for tumour subsets. HPV+ HNSC, HPV+ CESC, and even HPV- 
HNSC display a TCW motif in their sequence logos relative to Hepatocellular carcinomas or 
EBV+ Stomach Adenocarcinomas. B) Breakdown of TCW -> TKW fractions by tumour 
subset. HPV+ tumours are greatly enriched relative to viral HCC or EBV+ Stomach 
Adenocarcinomas, suggesting APOBEC mediated mutagenesis is not a general feature of 
virally driven cancers. Crossbars represent group medians.  
 
 
 
114 
 
Visualisation of sequence logos showed markedly lower levels of enrichment in non-HPV 
viral tumours (Figure 19A), and comparing distributions of TCW -> TKW fractions (Figure 
19B) revealed significantly higher medians in HPV+ tumours (0.29) relative to HCC (0.05, 
q.value < 2e-16, Wilcoxon’s Rank Sum Test) and STAD (0, q.value < 3.4e-16, Wilcoxon’s 
Rank Sum Test). This indicates APOBEC-mediated mutagenesis is not a generalised 
antiviral response that marks the genomic evolution of virally driven cancers.  
Enrichment for APOBEC-mediated mutagenesis is retained across 
mutational profiles of candidate driver mutations 
The genomes of cancers are punctuated by a wide range of mutations, some which have 
an impact on the fitness of cancer cells (drivers) and those that play a passive role 
(passengers). Driver mutations show distinct clustering and recurrence patterns allowing 
statistical classification, as implemented in the MutSig CV suite of tools.  
The exome-wide enrichment of APOBEC-mediated mutagenesis seen in HPV+ tumours 
raised questions of functional significance; whether TCW -> TKW mutations merely 
served to generate passenger mutations or played a critical role even in generation of 
driver mutations. This was tested by comparing distributions of TCW->TKW mutations in 
MutSig CV associated genes and distributions of TCW -> TKW mutations from exome-
wide sampling that was blind to being accorded driver-status by MutSig. Visual 
observation (Figure 20) and statistical testing using Wilcoxon’s Rank Sum Test suggested 
that distributions and differences between HPV+ and HPV- tumours were preserved 
within the MutSigCV gene subsets.  
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Figure 20: Distributions of TCW -> TKW fractions within whole exomes and MutSig genes 
by category. X axis = TCW -> TKW fraction. Y axis = density 
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APOBEC-mediated mutagenesis can determine mutational profiles 
and hotspot preference in cancer drivers.  
The analysis of genes most targeted by APOBEC mediated mutagenesis across the cohort 
of HPV+ tumours (HNSC and CESC) and HPV- HNSCs serving as a control highlighted 
PIK3CA as one of the most commonly mutated by APOBEC (2nd most common in CESC, 
3rd most common in HPV+ HNSC, and 3rd most common in HPV- HNSC).  In HPV+ 
tumours, where APOBEC activity is enriched, it was found that out of 78 PIK3CA 
mutations, 60 were TCW -> TKW, whereas in HPV- tumours, only 35/74 were of this 
type.  PIK3CA encodes the p110alpha catalytic subunit (a lipid kinase) of a 
Phosphoinositide-3-kinase that is activated by Receptor Tyrosine Kinases and RAS. Along 
with a kinase domain, this protein also contains a helical domain that activates this 
protein by interacting with a p85 subunit (Liu and Roberts 2006).  
Visualising the locations of these mutations suggested they mapped to two distinct 
mutational hotspots, skewed strongly towards APOBEC mediated mutagenesis in the 
HPV+ tumours relative to HPV- HNSCs (p = 0.0003, Chi-squared test for equality of 
proportions) (Figure 21A). Mutations in the helical domain (Exon 9) showed enrichment 
for TCW -> TKW mutations whereas those in the kinase domain (Exon 20) did not. 
Examining the hotspot mutations, the helical domain hotspot mutations (c.1624G>A and 
c.1633G>A) were found to be marked by TCW sites on the opposite strand, marking 
them out as driver mutations potentially driven by APOBEC mediated mutagenesis, 
whereas the kinase domain mutation hotspot (H1047R) was not (Figure 21B).  
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Figure 21: Illustration of PICK3CA hotspots and sequences at hotspots. Sites of helical 
hotspot mutations harbour a recognition site for APOBEC3B (TCA) on the non-coding 
strand. Figure 21B from (Henderson, Chakravarthy et al. 2014). 
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PIK3CA helical hotspot and kinase hotspot mutations tend to be equally common when 
examined across cancers and are both known to be potently transforming 
oncogenes(Kang, Bader et al. 2005, Liu and Roberts 2006, Huang, Mandelker et al. 
2007). It stands to reason that if APOBEC-drives PIK3CA helical hotspot but not kinase 
hotspot mutations, helical hotspot mutations should be found in tumours with high 
APOBEC activity at a higher frequency than kinase-hotspot mutations. In order to test 
this, I examined PIK3CA mutations in a dataset of 10 different tumour types (See 
Methods for details). Using TCW -> TKW fraction estimates and a binomial GLM 
regressing the TCW -> TKW fraction against mutation hotspot and controlling for tumour 
type revealed enrichment for APOBEC mediated mutagenesis in helical-hotspot mutated 
tumours (OR = 1.6, p < 0.001).  
 
Figure 22: Breakdown of TCW -> TKW fractions across multiple tumour types with PIK3CA 
hotspot mutations. Y axis = mutated hotspot, X axis = TCW -> TKW fractions. Black 
crossbars represent groupwise medians and colours represent tumour type. BLCA = Bladder 
Cancers, COADREAD = Colorectal, BRCA = Breast, HNSC = Head and Neck Squamous Cell 
Carcinoma, STAD = Stomach Adenocarcinoma, UCEC = Uterine Corpus Endometrial 
Carcinoma, GBM = Glioblastoma Multiforme, CESC = Cervical Squamous Cell and 
Endocervical Adenocarcinoma. 
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This association was also significant using an independence test comparing TCW -> TKW 
fraction distributions (Figure 22) between Helical-hotspot mutant and Kinase-hotspot 
mutant tumours (p = 0.001). These findings suggest that, independent of selection 
pressure, mutational processes can play a significant role in determining the spectrum of 
mutations that occur in a tumour and an interesting question for future work is to see 
how much mutational spectra can be delineated into the output of selective pressures 
acting on pre-existing pools of mutations which are to some level determined by 
mutational processes.  
Analysis of putative factors influencing APOBEC mediated 
mutagenesis. 
Previous studies have implicated APOBEC3B expression at the mRNA level as a 
determinant of APOBEC mediated mutagenesis, especially in breast cancer (Burns, 
Lackey et al. 2013) (Burns, Temiz et al. 2013). Given the differences between HPV+ HNSC 
and HPV- HNSC in APOBEC-mediated mutagenesis, I tested for, and found significant 
differences in the expression of most members of the APOBEC/APOBEC3 family (FDR < 
0.001 , Figure 23A) . However, in agreement with previous studies on cervical cancer 
(Ojesina, Lichtenstein et al. 2014), only weak, albeit statistically significant, correlations 
were found with all members of the APOBEC3 family (Figure 23B), suggesting that breast 
cancer is exceptional (Roberts, Lawrence et al. 2013). Viral gene transcript abundance 
and TCW -> TKW fraction were not correlated either.  
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Figure 23: A) mRNA expression of APOBEC family genes in HPV+ vs HPV- HNSCs, *** = FDR 
(BH) < 0.0001, Wilcoxon's Rank Sum Test. B) Correlation between TCW -> TKW fractions 
and mRNA expression of APOBEC family members. *** = FDR (BH) < 0.001, R = Spearman's 
Rho. 
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These findings however come with the caveat that current expression levels of both viral 
and APOBEC transcripts may not correspond to levels of APOBEC activity when these 
mutations were actually generated in the course of tumour evolution. 
 
Figure 24: Relationship between overall mutational load and APOBEC mutation load 
stratified by HPV status. For a given tumour type there is a conserved relationship between 
the APOBEC-induced and general mutational loads. Grey areas represent 95% Confidence 
Intervals for linear model fits.  
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A striking linear association was however found between the APOBEC and non-APOBEC 
mutational burdens in tumours (Figure 24), with the slope varying by tumour HPV 
status. In order to investigate the statistical relationship between tumour subtype, TCW 
-> TKW mutation ANOVA modelling was carried out. Model selection revealed the most 
variation (adjusted R2 = 0.37) in the TCW -> TKW mutation total was expained by HPV 
status and the non-APOBEC mutational load interacting (both explanatory variables 
significant at p < 0.01, model F statistic significant at p < 2.2e-16).It has been recently 
shown that the repair of mismatches is associated with the generation of APOBEC-
induced mutations (Chen, Miller et al. 2014) , as is the process of break-induced 
replication that generates ssDNA that serves as a substrate for cytosine deamination 
(Sakofsky, Roberts et al. 2014) and these processes offer potential explanations for the 
relationships observed between TCW and non TCW mutations (NB – this approach was 
originally devised for the interim analysis published in (Henderson, Chakravarthy et al. 
2014) by Stephen Henderson).  
Chapter Conclusions.  
Until recently, it had been unclear if HPV, following the constitutive inactivation of E6 
and E7 and accompanying transcriptional and epigenetic changes it could directly 
induce, was responsible for shaping the evolution and selection of subsequent genetic 
hits required for full transformation or just generated a population of cells with 
dysregulated p53 and pRb function that could then acquire additional hits through 
mutational processes in which HPV directly played no part. The evidence presented in 
this chapter suggests that APOBEC-mediated cytosine deamination is a connecting link 
between anti-HPV antiviral responses and the evolution of these additional mutations. 
123 
 
In HPV+ HNSC, which is traditionally associated with non-smokers and younger patients, 
there appears to be greater dependence on APOBEC to generate the necessary 
mutations for malignant transformation, and there are features of the transcriptional 
signature associated with HPV-driven tumourigenesis that potentiate APOBEC activity.  
While the correlation between APOBEC expression and activity was found to be weak, it 
is important to realise that expression levels at sampling may not correspond to 
expression levels when the mutations in these genomes were generated, which may 
have occurred across a wide range of time-points in tumour evolution.  
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Chapter 5: Common Epigenetic 
Profiles Unify HPV-driven cancers 
across tissues.  
The relationship between various datasets used for signature discovery, training and 
validation are summarised in a flowchart presented as part of Appendix A3.  
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Statistical analyses establish a comprehensive catalogue of DNA 
methylation changes in HPV-driven tumours and point towards a 
hypermethylator phenotype.  
Using a discovery set of 844 samples (see methods for class/tissue/HPV detection 
method breakdown) I defined signatures of methylation variable positions (MVPs) and 
Differentially Methylated Regions (DMRs) for HPV-driven tumours that could distinguish 
them from HPV- tumours and normal controls that arose in similar anatomical sites. 
Using a limma based pipeline for MVP-calling, I identified a total of 8225 MVPs 
differentially methylated with a beta-value median shift of at least 20% at an FDR (Two-
step BH adjusted) of 0.001 or less (Figure 25).  The signature was robust to tissue type, 
with tissue adjusted analyses yielding 6870 of the same MVPs at the same thresholds.  
Of these MVPs, 6753 were hypermethylated in HPV+ cancers, and only 1472 were 
hypomethylated, pointing towards a hypermethylator epigenotype (p < 2.2e-16, 95% CI 
= 0.81 – 0.82 towards hypermethylation, binomial test against null probability of no 
skew).  In addition to MVPs, analysis was also conducted using fDMR. This approach 
clusters probes by annotation based on number of statistically significant MVPs, and 
functional annotation. It then accounts for the spatial correlation of the probes in the 
candidate DMR and performs Stouffer-Liptak p.value combination to identify statistically 
significant DMRs. 781 DMRs, mapping to 3328 and 508 hypermethylated and 
hypomethylated MVPs respectively, were discovered to be associated with HPV status, 
with each DMR containing at least 3 MVPs (defined as described above) at DMR FDR < 
0.001 and a DMR-median shift of 20% in the beta-value.  
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Of these, 664DMRs were hypermethylated and 117 were hypomethylated in HPV+ 
samples, again supporting a hypermethylator epigenotype at the DMR level (CI = 0.82 – 
0.87, p < 2.2e-16,binomial test).  
 
Figure 25:  Volcano Plot showing differences between HPV+ and HPV- samples. X axis = 
Beta value difference (dB > 0 when hypermethylated in HPV+ tumours). Y axis = -log10 
(False Discovery Rate). Colours indicate relationship between probes and CpG Island related 
annotations. 
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The Global Hypermethylator Phenotype Extends to Most Categories 
of HM450k probes.  
Having established the initial methylation signature for HPV-driven tumourigenesis and 
having discovered a global trend towards hypermethylation, I examined skews towards 
hypermethylation across CpG-density and transcript-centric categories of probes to 
decipher patterns of global methylation in these cancers.  
 
Figure 26: Numbers of hypermethylated vs hypomethylated probes by probe and signature. 
X axis = 95% CI of probability of hypermethylation , with vertical line representing 
equiprobability of hypermethylation and hypomethylation 
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Apart from CpG shelf associated probes that mapped to the DEG-linked MVPs, and 
3’UTR probes that mapped to DMRs and all MVPs, and gene body probes that mapped 
to DEG-linked DMRs, all other categories demonstrated a distinct skew towards DNA 
hypermethylation in HPV+ tumours (FDR < 0.05) (Figure 26).  
 
Figure 27: Distributions of average beta-value in differentially methylated probes and all 
450k probes respectively. Y axis = average methylation value per sample, colour represents 
Tissue type, crossbars represent group medians. 
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While previous research has reported HPV-associated hypermethylation, it has been 
based on comparisons of HPV+ and HPV- cancers with no normal samples available 
(Lechner, Fenton et al. 2013). These patterns could in fact have been produced by 
hypomethylation in HPV- tumours rather than hypermethylation in HPV+ tumours, 
relative to normal tissue. However, examining the distributions of per-sample means for 
MVP associated probes in normal epithelial samples (Cervix/Head and Neck), HPV- 
cancer and HPV+ cancer showed marked hypermethylation in the latter relative to the 
former two groups (p < 2.2e-16) (Figure 27). When considering array-wide distributions 
however, differences were not significant between these categories at FDR < 0.05 and 
shifts in distributions were minor. The attribution of a hypermethylator phenotype to 
HPV+ tumours relative to normal tissue and HPV- tumours therefore remains dependent 
on whether comparisons are made within differentially methylated probes or 
universally.   
Pan-tissue epigenetic signatures are useful for classification by HPV 
status.  
Having derived methylation signatures at the probe and region levels for HPV-driven 
tumourigenesis, I examined if the features contained therein could serve as a basis for 
accurate classification of HPV-status by developing Random Forest classifiers and 
visualising clustering patterns of feature methylation values. When the discovery set was 
initially visualised on heatmaps (Figure 28), the probes in these signatures stratified 
samples into distinct clusters that track with HPV status. Evaluation of these features for 
classification using Random Forest classifiers produced highly reliable classifiers. 
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 The MVP signature returned Positive (PPV) and Negative (NPV) Predictive Values (See 
Methods) of 0.96, while the DMR signature returned values of 0.95 and 0.94 when based 
on out-of-fold predictions, serving to internally validate these signatures.  
 
Figure 28: Pan-tissue methylation signatures for HPV-driven tumourigenesis group HPV+ 
tumours together in distinct blocks. Columns represent samples and rows represent probes. 
Intensity represents beta value for methylation. 
 
The classifier was then applied to independent datasets to test concordance with HPV 
status as derived by other means. In a small dataset of Penile Carcinomas (n=26, HPV+ = 
7) (PeCa) (Figure 29A), where HPV status was only known on the basis of p16 staining 
and DNA in-situ hybridization, PPV of 0.83 and NPV of 0.89 (DMR), and PPV of 1.00 NPV 
of 0.9 (MVP) were observed.  It is possible that some of the misclassified samples were 
not truly HPV+ given some samples had HPV at less than 1 copy/cell, and evidence for 
active HPV transcription was lacking.  
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Figure 29: (A) Patterns of MVP and DMR signature probe methylation in Penile Carcinomas. 
(B) MVP and DMR signature methylation in an independent cohort of No rwegian Cervical 
Cancers.  Intensities represent beta-values, for PeCa, annotations represent HPV status 
prediction and HPV viral load classification. For Cervical Cancers, annotations represent HPV 
status by RNA-seq (Normal samples assumed HPV-) , Random Forest predictions and 
Cancer/Normal status. 
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Application to an independent Cervical Cancer dataset from Norway, with samples 
obtained from our collaborator Helga Salvesen and samples processed by Dr Andrew 
Feber and UCL Genomics, (29 Normal, 77 tumour) suggested that the vast majority of 
cancers recapitulated methylation patterns seen in the discovery set (Figure 29B). 
However, there were multiple samples that were misclassified, resulting in high PPV 
(1.0) and low NPV (MVP = 0.69, DMR = 0.66) that were HPV+ by the detection of viral 
transcripts, despite clustering patterns clearly separating HPV+ and HPV- samples.  
This indicated the occurrence of overfitting or between-batch technical variation that 
the normalisation procedure could not have accounted for. These explanations were 
tested by first splitting the discovery set into two, training on one, and then using the 
other half as an independent test sets. For both the MVP and the DMR signatures, 
internal cross-validation accuracy was better than independent validation using the 
other half (Kappa = 0.86 vs 0.91 for DMRs, 0.88 vs 0.93 for MVPs).   
Models trained on half the discovery set also demonstrated better performance in the 
Norwegian cohort compared to those trained on the entirety of the discovery cohort; 
(NPV for MVPs = 0.79, DMRs = 0.76, vs <0.7 for full model) implicating overfitting as the 
reason for worse performance in independent datasets. Potential technical variation 
between datasets was also identified upon visualising an MDS plot of MVPs (Figure 30). 
Finally, estimating model performance using cross-validation while training a Random 
Forest on the Norwegian cohort using the signatures defined with the discovery set 
again demonstrated markedly higher accuracy (For MVPs, Kappa = 0.93, PPV = 0.91, NPV 
= 1. For DMRs Kappa = 0.86, PPV = 0.88, NPV = 0.97), confirming poor performance was 
not motivated by poor feature selection.  
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Figure 30: MDS plot of signature MVPs in the discovery and Norwegian cohorts, which were 
both normalised separately using Functional Normalisation. Some samples cluster by 
dataset and display dataset specific relationships between groups defined by HPV status, 
hinting at batch effects. 
 
These findings, taken together, highlight the utility of pan-tissue DNA methylation 
profiles as a marker for HPV-driven tumourigenesis, highlight the threat of overfitting, 
and finally point to an unmet need for single-sample normalisation procedures to deal 
with technical variation on the 450k platform. 
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Integrating methylation with matched expression data identifies 
novel HPV-associated transcriptional changes.  
The discovery dataset in large part was derived from samples processed by the Cancer 
Genome Atlas, ensuring the availability of matched RNA-seq samples for investigating 
gene expression. In total, out of the 844 samples in the curated Pan-tissue dataset, 794 
had matched RNA-seq data.  
Limma-trend analysis was used to identify genes that were differentially expressed and 
methylated as canonically expected for DNA methylation (overexpressed with increasing 
gene body methylation, and underexpressed with increasing promoter/1st Exon /5’UTR 
methylation).  
In addition to these candidates, additional annotation was also performed to uncover 
long-range changes in expression regulated by enhancer methylation. Methylation at 
distal regulatory regions has been shown to be better correlated with gene expression 
changes than promoter methylation, and large profiling projects such as the FANTOM5 
consortium have used CAGE-seq to sensitively document a wide array of enhancers that 
are marked by bidirectional transcription in a broad set of samples, along with 
establishing putative correlated gene pairs across tissues. In order to identify such distal 
methylation changes, the set of MVPs was reduced to those overlapping known 
FANTOM5 enhancers. 411/530 of these were found to be actively transcribed in at least 
one out of a collection of 11 samples of normal and cancer tissue types profiled in the 
discovery set at more than 0.5 tags/million.  
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Figure 31: A) Quadrant plots showing genes that overlap differentially methylated 
probes/regions and are differentially expressed. B) Heatmaps of gene expression in 794 
samples that overlap the methylation signature discovery set. Methylation associated 
Differentially Expressed genes accurately cluster HPV+ and HPV- samples. 
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These were then checked for inverse differential expression of correlated gene pairs.  Of 
these, ultimately, 23 enhancer probes were differentially methylated, and were linked to 
canonically differentially expressed genes.  Out of all the probes in the MVP signature, 
684 probes mapped to 243 DEGs while 93 DMRs were canonically associated with 84 
DEGs (Quadrant-plot of Expression-Methylation relationships in Figure 31A). The 
functional MVP and DMR signatures, and associated DEGs, result in accurate clustering 
of samples by HPV status when visualized on heatmaps (Figure 31B).  The low 
proportion of DNA methylation changes associated with gene expression changes is not 
surprising as cancer cells with mostly ablated methyltransferase activity fail to derepress 
genes on a large scale (Blattler, Yao et al. 2014). Previous studies involving HPV-driven 
cancer methylomes, including the analysis of HNSC methylomes by (Lechner, Fenton et 
al. 2013), Penile Cancer methylomes (Feber, Arya et al. 2015) and Cervical cancers by 
(Farkas, Milutin-Gasperov et al. 2013) have all been constrained by the non-availability 
of matched expression data.  The sets of epigenetically regulated transcriptional events 
derived here offer refined understanding of how epigenetic dysregulation shapes 
transcriptional events in HPV driven cancers.  
Pathway Analysis contextualises the contribution of DNA 
methylation to transcriptional dysregulation in HPV+ tumours.  
Efforts to characterize the functional context of canonically regulated Differentially 
Expressed genes was initially carried out using IPA for both DMR-associated and MVP-
associated DEGs. No significant pathways or upstream regulators were discovered for 
DMR-associated DEGs.  
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Pathway analysis of MVP-associated genes however uncovered interesting sets of 
pathways dysregulated by DNA methylation. Two canonical pathways were found to be 
enriched at BH-FDR < 0.05; Embryonic Stem Cell Differentiation into Cardiac Lineage and 
Transcriptional Regulatory Network in Embryonic Stem Cells.  
DMRs and MVPs not mapping to distinct pathways have two implications – either 
epigenetic events may simply contribute to transcriptional remodeling by dysregulating 
specific nodes in networks and pathways to which other mechanisms of dysregulation 
also contribute, or they simply comprise a passenger phenomenon.  If the former 
hypothesis is true, it follows individual DMRs or MVPs should map to genes that are 
either part of global transcriptional networks associated with HPV+ tumourigenesis or 
have gene functions directly relevant to HPV-driven tumourigenesis. Correlation analysis 
and testing for overlaps with either the HPV-metasignature or literature searches for 
associations with HPV-driven tumourigenesis were then used to nominate such genes.  
Three DMRs were found to be associated with the HPV-metasignature, and displayed 
differential expression by HPV status and a strong correlation between methylation and 
expression. SYCP2 (R=-0.75), HLTF (R=-0.60) and RPA2 (R=-0.58, all Spearman’s Rank 
Correlation) and were hypomethylated in HPV+ tumours (Figure 32A). Amongst the 243 
canonical MVP-associated genes, 10 genes were found to overlap with the HPV-
metasignature (p = 0.0001 for enrichment, randomisation test) . These findings together 
suggest epigenetic alterations contribute significantly towards overall transcriptional 
dysregulation.  
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Figure 32: A) DMRs overlapping with the HPV-metasignature B) Novel DMRs are highly 
correlated with gene expression and show divergent transcriptional patterns by HPV status. 
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In addition to the epigenetic changes described above, several DMRs are strongly 
correlated with expression and have either known roles in HPV-driven tumourigenesis or 
are unexplored and novel candidates (Figure 32B). 
PITX2 is a promoter that is highly methylated in HPV+ tumours relative to HPV- tumours, 
and is a candidate for a driver epigenetic event because PITX2a has previously been 
shown to actively interfere with HPV18 E6-mediated degradation of p53 by binding to 
the former (Wei 2005), disrupting an interaction that is central to HPV-driven 
tumourigenesis.  
RPA2, which is also dysregulated in the HPV-metasignature, is a regulator of mitotic 
catastrophe and maintains replication fork integrity after stalling due to replication 
stress (Murphy, Fitzgerald et al. 2014).    
Novel candidates include SCAND3, which is not only associated with a DMR and is 
strongly correlated, but is also associated with validated long-range enhancers. SCAND3 
encodes a member of a family of retrotransposon-derived transcriptional regulators 
(Llorens, Bernet et al. 2012) and the functional significance of this gene is unclear.  
Other novel candidates regulated epigenetically include GATA4, which encodes a 
transcription factor that is known to be a tumour suppressor in malignant astrocytomas 
(Agnihotri, Wolf et al. 2011), LIMD2, a known prometastatic factor (Peng, Talebzadeh-
Farrooji et al. 2014) and ADARB2, which encodes a member of the family of RNA 
Adenosine Deaminases.  
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A tale of two populations: Follow-up analysis on KRT7 methylation 
patterns suggests HPV-type associated tropism for distinct 
precursor cell populations.  
Other DMRs may have implications in explaining the cellular origins of these HPV+ 
tumours. It has been postulated that cervical cancer almost exclusively arises from a 
squamocolumnar junction layer of epithelial cells with foetal origins (Herfs, Yamamoto 
et al. 2012) and one of the defining markers of this population is high levels of KRT7 
expression, which is marked in HPV+ tumours by a hypomethylated promoter-DMR 
associated with overexpression and strong correlation (R= -0.7, Spearman’s Rank 
Correlation, Figure 33A) , suggesting that KRT7 expression and hypomethylation may act 
as a cellular marker for the expansion of squamocolumnar junction cells. Interestingly, 
comparing distributions of DMR methylation and KRT7 expression suggested differential 
expression between HPV+ Head and Neck Cancers and Cervical Cancers.  
Visualising the distributions of KRT7 expression and promoter DMR methylation in HPV+ 
HNSC (mostly HPV16+) and CESC positive for HPV16/HPV18/HPV45 demonstrated that 
the distributions of HPV16+ CESC and HPV+ HNSC largely overlapped, whereas patterns 
differed for HPV18+ and HPV45+ compared to HPV16+ cervical cancers or HNSC, with 
very high expression levels of KRT7 (and very low methylation levels) the norm in 
HPV45+ / HPV18+ samples (Figure 33B). This led to detailed analyses of 
squamocolumnar junction marker genes in HPV+ tumours in this dataset.  
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Figure 33: A) KRT7 Expression and promoter DMR methylation are strongly anti-correlated. 
B) Violin plots demonstrate variations in KRT7 Expression and Methylation by group. FDR 
from Holm correction on pairwise Wilcoxon's Rank Sum Tests. HPV16, HPV18 and HPV45 
represent groups of cervical cancer samples with these HPV types. The small number of 
adenocarcinomas in the dataset makes confounding by cervical histology unlikely.  
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Signature gene lists for squamocolumnar junction cells were obtained relative to 
columnar and squamous epithelial cells from (Herfs, Yamamoto et al. 2012) (See 
Methods), and HPV+ HNSC/ HPV45+/HPV16+/HPV18+ CESC were Consensus clustered 
on this basis. Two clusters were identified as the most robust solution, and one cluster 
contained the vast majority of the HPV18+ and the HPV45+ tumours (Figure 34). 
 
 
Figure 34: Consensus Clustering based on a squamocolumnar junction cell expression 
signature identifies that HPV16 may infect cells not marked by this signature, whereas 
HPV18 and HPV45 are more restricted. 
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85% of HPV+ HNSC and 57% of HPV16+ CESC mapped to the Junction-low signature, 
suggesting that while HPV16 could transform a broad range of cellular populations that 
differed in patterns of squamocolumnar junction gene expression, whereas HPV45 (73% 
Junction-High) and HPV18+ (77% Junction-High) tumours were more restricted to a 
cellular population defined by the high-expression cluster.  
The implications of these findings are two-fold. Firstly, the abundance of the types of 
cells analogous to the Squamocolumnar Junction cells of the Cervix may determine what 
HPV types infect and transform what tissues and at what frequency, and secondly, 
different HPV types may be associated with tumours that display heterogeneous 
transcriptional and epigenetic signatures, and consequently behaviour when 
transformed. The latter possibility is comprehensively evaluated in the next chapter.   
Chapter Conclusions  
The work in this chapter contains the largest analysis of methylomes from HPV+ cancers 
and HPV- tumours that arise in similar tissues. A signature of global hypermethylation 
marks HPV+ tumours, even if only a small fraction of the genes differentially methylated 
between HPV+ and HPV- tissues display evidence for associated expression changes. 
DNA methylation appears to contribute to transcriptional dysregulation in concert with 
other mechanisms that alter transcription and does not act as a mediator of co-
ordinated sets of transcriptional changes.  
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Despite this, putative candidate DMRs like those at PITX2 likely regulate the expression 
of candidate driver epigenetic events, and one of the future challenges that may emerge 
in the analysis and understanding of methylation data is the development of methods 
that can infer driver methylation events; a task that has been made possible for 
mutations using multiple criteria. 
Finally, DNA methylation, being amenable to be used as a biomarker, renders the 
signatures defined in this chapter a source for biomarkers that may serve to 
unambiguously identify HPV+ tumours in a clinical setting.  
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Chapter 6: Categories of Viral 
Classification Correlate with Clinical 
and Molecular Heterogeneity within 
HPV+ Cervical Cancers.  
The main steps of analyses undertaken in this chapter have been described in a 
flowchart in Appendix A3.  
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Molecular heterogeneity is a function of taxonomic variation in 
Human Papillomaviruses. 
Of the various cancers caused by HPV, HPV16 predominates in cancers of the head and 
neck, whereas in cervix HPV18 and HPV45 also play a significant role, with minor 
contributions from other HPV types (Saraiya, Unger et al. 2015). The overrepresentation 
of HPV16 across all HPV-driven cancers raises questions of whether there are critical 
differences between HPV16-driven tumours and other HPV driven tumours in terms of 
the molecular profiles they establish, the cells of origin for the tumours they cause, and 
given the ability of HPV16 to induce the pan-tissue signatures described earlier in this 
thesis, and finally if differences in viral genomes translate to different clinical behaviour 
through establishment of varied molecular profiles.  
HPV18+ cancers have been associated with poorer outcomes following radical 
hysterectomies in early stage cervical cancer (Burger, Monk et al. 1996), likely as a 
consequence of greater extents of invasion and nodal metastasis (Im, Wilczynski et al. 
2003). More recently, it was shown that a small subset of 30 CpGs (referred to as F30 
hereon) sites classified cervical cancers into two groups with different prognostic 
outlooks, with one of the groups predominantly containing HPV16+ cancers (Feber, Arya 
et al. 2015).  In order to investigate the relationship between clinical outcomes and 
taxonomic categories of HPV, and to catalogue the molecular heterogeneity mediating 
these associations, RNA-seq was used to allocate HPV type to a total of 307 tumours in 
total, followed by analysis of transcriptome and epigenomic variation (HPV status calling 
by Stephen Henderson and from (Tang, Alaei-Mahabadi et al. 2013)).  
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HPV-types were then allocated to their respective clades and restricted to A7 and A9, 
comprising 291 tumours and into the F30 clusters. The original F30 publication only 
examined a subset of cervical cancers, so I initially checked and confirmed that F30 
clusters showed associations with Clade (89.1 % of A7, and 16% of A9, were negative for 
the good survival F30 signature, OR=5.5, p = 1.6e-12, Fisher’s exact test) and Overall 
Survival (HR= 0.38 if F30+, p = 0.001), matching expectations on both counts.  
 
Figure 35: Differentially Expressed Genes (2FC, FDR < 0.01) (A) and canonically functional 
MVPs (delta Beta > 0.1, FDR < 0.01) (B) from comparing Clade A7 with A9. Annotation 
Ribbon indicates clade.  
Having established that HPV clade was associated with a molecular pattern of prognostic 
utility, comparative analyses of methylomes and expression signatures between Cervical 
Squamous Cell Cancers (n = 233) driven by HPV types in Clades A7 and A9 were carried 
out, and documented 596 differentially expressed genes (2FC, FDR < 0.01) and 592 MVPs 
(mean beta-value difference 0.1, FDR < 0.01) that were canonically associated with 252 
differentially expressed genes (2FC, FDR < 0.01) (Figure 35).  
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Comparing survival between clades revealed differences in outcomes (HR = 0.512, p = 
0.045, LRT p value = 0.05) overall and a bigger difference when comparing clades within 
early stage (Stage I and Stage II) tumours (HR = 0.39, p = 0.018, LRT p value = 0.0242). 
These initial analyses suggested that early stage tumours showed more marked clade 
associated clinical differences and established that HPV clades associate with 
molecularly distinct categories, in the process motivating the use of early stage tumours 
as a dataset to study molecular differences in tumours as a function of taxonomic 
classification of the HPV-types driving them.    
 
 
Figure 36: A) Survival differs by HPV type with HPV16 and HPV45 occupying opposite ends 
of the prognostic spectrum (Stage I and II tumours). X axis = time in days, Y axis = risk of 
death B) Heatmaps showing 646 DEG and 614 expression associated MVPs respectively in 
Stage I and Stage 2 squamous cell cancers ( n = 127 ). Annotation ribbon depicts HPV type 
(HPV45 in orange, HPV16 in red). 
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In order to examine the interplay between taxonomic categories and clinical outcomes 
at higher taxonomic resolution, and to derive signatures for clinical stratification, I 
compared survival by type in early-stage tumours, and found that HPV16 driven tumours 
and HPV45 driven tumours occupied opposite ends of the clinical outcome spectrum, 
with HPV18+ tumours displaying intermediate survival trends (Figure 36A).  
Modelling transcriptional differences between HPV16 and HPV45+ early-stage tumours 
identified 646 genes differentially expressed between HPV45 and HPV16 positive 
tumours (FDR=0.01, FC > 2).  Similarly, analysis of methylation data and subsequent 
integration with differentially expressed genes yielded a signature of 613 MVPs, of 
which 225 genes were also present in the transcriptional signature compatible with the 
canonical function of DNA methylation. Heatmapping and clustering highlighted general 
separation of HPV45 and HPV16 driven tumours using the cfMVP and whole-
transcriptome DEG signatures (Figure 36B).   
Pathway analysis points to an inflammatory phenotype in HPV45 
driven tumours.  
IPA core analysis was then carried out to characterise pathway signatures while limiting 
the database to experimentally observed direct interactions. Some of the top canonical 
pathways included Granulocyte and Aggranulocyte Adhesion and Diapedesis, and 
amongst canonical pathways with activation z-scores and clear-cut activation states, one 
of the top hits for activation in HPV45+ tumours was TREM1 signalling, a pathway 
previously implicated as being essential for hepatocarcinogenesis (Wu, Li et al. 2012), 
associated with the secretion of multiple proinflammatory cytokines.  
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TREM1 signalling is known to be induced in tumour associated macrophages and the 
expression profiles for these HPV45+ tumours showed significant upregulation of the 
macrophage marker MCP1 and PTGS1 and 2, which are known to induce TREM1 
activation (Yuan, Mehta et al. 2014). In toto the HPV45 signature, which contains 
multiple inflammatory cytokines including interleukins (IL11, IL18, IL1B, IL24, IL6, IL8) 
and other immune mediators (CCL2, CXCL2, CXCL3, CXCL5, TNF-alpha and TNFAIP6) 
points to the presence of an aggressive, inflammatory phenotype associated with 
HPV45.   
The HPV45 transcriptional signature points to metastatic behaviour 
Gene set enrichment using IPA's Diseases and Functions ontology identified cellular 
movement as the most activated pathway, with 85 out of 121 genes in the set expressed 
consistently with increased metastatic potential (gene set visualised in Figure 37).  
The genes overexpressed in this pathway with prometastatic associations included,  
amongst others, SNAI1, which is a master regulator of epithelial mesenchymal transition 
and is associated with worse prognosis and chemoresistance in metastatic cancers 
(Kaufhold and Bonavida 2014), fibronectin 1, which is known to trigger EMT-associated 
transcriptional cascades (Park and Schwarzbauer 2014), RHOF, which has been 
implicated in the formation of pseudofilopodial protrusions needed for invasion through 
basement membranes(Reymond, d'Agua et al. 2013), and VEGFC, a VEGF isoform 
implicated in the process of tumour-associated lymphangiogenesis (Skobe, Hawighorst 
et al. 2001) . 
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Figure 37: The "Cell Movement" gene set that is the top enriched gene set in HPV45+ 
tumours. Red = overexpressed in HPV45+ tumours, blue = underexpressed. Dark orange = 
expression change consistent with increased cell movement, light orange = expression 
change inconsistent with increased cell movement.  
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Upstream regulatory analysis identifies putative regulators of the 
HPV45 expression signature.  
The top five candidate regulators inferred to be activated in HPV45+ tumours were 
SMARCA4, EZH2, RELA,  FOXL2, and  HIF1A. Interestingly, RELA is an NF-kB effector, and 
the co-ordinated activity of EZH2 and RELA in complex has been linked to the 
modulation of genes implicated in epithelial mesenchymal transition (Lee, Li et al. 2011), 
and some of the genes defined to be coregulated by EZH2 and RELA are also inferred to 
be coregulated by both by IPA (TNF,IL6, PTGS2 ).  
Beta-catenin signalling was also inferred to be activated in HPV45+ tumours, and is 
consistent with the previously documented association of beta-catenin cellular 
localisation as a correlate of survival (Zhang, Liu et al. 2014).   SMARCA4 (BRG1) 
interestingly has been implicated in the transcriptional activity of the HPV18 (He and Luo 
2012) promoter before and it will be of interest to verify if the relative inferred 
activation of this gene may correspond with differential dependence by HPV type.  
The functional context of HPV45 associated epigenomic changes.  
IPA analysis of DMR-associated differential expression genes did not highlight many 
canonical pathways, upstream regulators or diseases and function associations of 
interest, leading us to focus on the much larger set of gene expression changes 
associated with MVPs.  Upstream regulatory analyses again implicated SMARCA4 and 
CTNNB1 as being activated, and the aryl-hydrocarbon receptor to be inhibited. 
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 Diseases and functions ontology analysis resulted in a list of associations including cell 
migration and proliferation amongst the top scoring hits for activated 
pathways/processes. These results lend an additional layer of support to the hypothesis 
that an aggressive, prometastatic signature characterises the behaviour of HPV45+ 
disease.   
HPV45 associated molecular signatures are of value beyond HPV45. 
It was apparent from the heatmaps presented in (Figure 36B) that certain HPV16+ 
samples clustered with HPV45+ samples, suggesting the HPV45 associated signature 
may be of relevance more broadly for outcomes in cervical cancers, including in 
stratifying the intermediate survival HPV18+ tumours by aggressiveness. The availability 
of both methylation and expression signatures, which have different distributions and 
scales demanded the development of a multiplatform clustering approach, which led to 
the use of a random forest proximity matrix to represent a joint Feature x Sample matrix 
consisting of probes and transcripts from both signatures. The joint clustering that 
resulted from this identified 7/18 HPV18+ tumours and a small subset of HPV16+ 
tumours (8/119), that clustered with HPV45 driven tumours (Figure 38A). Comparing 
outcomes suggested these clusters retained prognostic performance overall (HR = 10.08, 
95% CI = 4.07 - 24, q = 5.8e-7) when stratified by stage, and when restricted to early 
stage HPV16 and HPV18 tumours alone and stratified by stage (HR = 15.48, CI = 4.7 - 
49.9, q = 6.9e-6), and when tested as part of a Cox regression model that was stratified 
by both type and stage (HR= 18.1, CI = 5 - 65.8, q = 1e-5). These signature derived pan-
type clusters were therefore a good starting point for biomarker development to aid 
clinical stratification of patients.  
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Figure 38: A) Heatmaps of HPV45-associated cfMVPs (left) and DEG (right) across all Early 
Stage I and II HPV16/18/45+ Cervical squamous cell cancers in the TCGA cohort. Cluster 
allocation is derived from proximity matrix of samples based on both data types. Multiple 
HPV16 and HPV18+ tumours display HPV45-like profiles. B) Heatmap of MVPs (delta-Beta 
0.3, FDR < 0.01) between HPV45-like and HPV16-like clusters of Stage I and II cervical 
squamous cell cancers.  
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Machine learning yields a DNA-methylation classifier for 
aggressiveness associated clusters. 
In order to develop a DNA methylation classifier for potential clinical application, I 
initially compared the HPV45-like and HPV16-like clusters of tumours and derived a 
signature of strongly differentially methylated probes (FDR < 0.01, beta value difference 
0.3) (Figure 38B). This was then used to train a set of classifiers (Random Forest, k-
Nearest Neighbour, Support Vector Machine, Gradient Boosted Machine, Nearest 
Shrunken Centroid, GLMnet). Each model was evaluated using Kappa values derived 
from aggregates of out-of-fold predictions to estimate ability to recapitulate the original 
clusters. The Support Vector Machine was found to be the best model (Kappa = 0.96, 
PPV= 0.98 for HPV-16 like tumours, NPV = 1.00). The model was then applied to 
independent methylome datasets with accompanying clinical information from Norway 
(n = 87) to validate prognostic utility. The model stratified patients by survival after 
controlling for stage and histology with HPV45-like tumours exhibiting significantly 
worse outcomes (HR = 4.134, p = 0.048, 95% CI = 1.01 – 16.8) after controlling for stage 
(Kaplan-Meier Curve of the cohort is in Figure 39). Notably, amongst driver genes only 
KRAS and PIK3CA are mutated disproportionately (FDR < 5%) between the two clusters 
in TCGA, suggesting the bulk of prognostic differences are mediated by the epigenome 
and the transcriptome. It is notable that when Histology alone was evaluated as a mode 
of stratification while adjusting for stage, none of the histological subtypes attained 
significance at p < 0.05.  At the time of writing, additional processing of samples from an 
Austrian cohort of Cervical cancers was underway to enable further validation of the 
aggressiveness signature in a more powerful cohort. 
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Figure 39: Kaplan-Meier Curves of predicted HPV45-like and HPV16-like tumours within the 
Norwegian Cohort of Cervical Cancers. X-axis = time in days. Appendix A5 plots the K-M 
curves by histology, serving to explain the marginal P-value observed here.   
Aggressiveness Clusters Span Histology despite Cell-of-origin 
preferences. 
Having established that HPV45 and HPV18+ tumours tended to display high-expression 
of Squamocolumnar-junction cell genes (Chapter 4) I tested for associations between 
Junction-signature cluster and Aggressiveness allocation, which revealed a strong 
tendency for HPV45-like tumours to also display high levels of squamocolumnar junction 
transcription (OR=4 for a Junction-High tumour to be HPV45-like, p = 7.64e-5, Fisher’s 
Exact Test), suggesting that HPV45-like tumours may arise from a distinct cellular 
population to which HPV18 and HPV45 are restricted.  
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Figure 40: Heatmap of SVM-based Aggressiveness Class allocation in the Norwegian Cohort. 
Cluster = Allocated Class, Histology = histopathologic classification. 
 
Visualisation of class allocation and histology in the Norwegian cohort indicated 
enrichment for adenocarcinomas in the HPV45-like cluster. Formally testing this 
hypothesis in the entirety of the TCGA CESC cohort indicated adenoid 
(adeno/adenosquamous) carcinomas were far likelier to be HPV45-like (36%) than 
squamous carcinomas (20%) (OR = 0.41, p = 0.01).  
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Chapter Conclusions  
Cervical Cancers are unique amongst HPV+ tumours in terms of being driven by multiple 
common HR-HPV types, and previous research has hinted that different HPV-types may 
be associated with different molecular profiles and pathology. The work in this chapter 
firmly establishes the concept that different HPV-types, when grouped on the basis of 
taxonomic categories such as clade/species and HPV type, are associated with large-
scale transcriptional and epigenetic differences, either as the proximate cause or as a 
consequence of cellular background and wiring. HPV45+ tumours were particularly 
aggressive in the TCGA CESC cohort and displayed molecular profiles that had prognostic 
value across the cohort, culminating in the development of a classification scheme that 
stratifies patients by prognosis. Additional validation confirmed the existence of these 
subtypes in an independent cohort and again hinted at the markedly aggressive nature 
of HPV45-like tumours, in a single-center cohort with well-annotated clinical data, which 
works-around the multi-centre nature of TCGA clinical data and the lack of cause-specific 
mortality information in the latter. 
Statistical analysis suggests that HPV45-like tumours are often enriched for a 
Squamocolumnar Junction gene expression profile and the molecular profiles that 
underpin them cut across lines of histology. This offers a new approach to classifying and 
managing cervical cancers that goes beyond and complements constructs like staging 
and histology that currently define clinical management. A critical open question at this 
point, meriting future investigation, is whether different HPV types are sufficient causes 
for the induction of these molecular profiles. 
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The Immune Landscape of HPV-
driven tumours.  
The analyses carried out in this chapter are summarised in a flowchart in Appendix A3 
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Background  
Findings presented in Chapter 3 demonstrated that the immune system could be a 
potential mediator of prognosis amongst subsets of HPV-driven tumours that are 
otherwise molecularly similar. In Chapter 6 I demonstrated the existence of a distinct set 
of molecular signatures associated with HPV45 with transcriptional patterns suggestive 
of pro-inflammatory signalling and TREM1 activation, and then demonstrated that these 
patterns were also associated with subsets of HPV18+ and HPV16+ cancers.  
The viral origin of these tumours suggests that as they develop, they must evolve to 
evade recognition by the immune system. Multiple lines of evidence support this 
assertion – the markedly increased risk of HPV-associated malignancies in HIV/AIDS 
patients with immune system dysfunction(Palefsky 2009), amplifications in antiviral 
genes that mediate episome clearance (Mine, Shulzhenko et al. 2013), the association 
between anti-HPV16 E6 antibodies and risk of full blown malignancy in candidate 
patients for HPV+ OPSCC and to a lesser extent in genital cancers (Kreimer, Brennan et 
al. 2015), the association of germline variation in MHC and HLA genes with risk for 
cervical cancer (Chen, Cui et al. 2015) .  
In addition to this, a substantial body of work has emerged around how the evolution of 
tumours is shaped by the immune system through the process of immunoediting (Mittal, 
Gubin et al. 2014), where the immune system acts to exert selective pressures on 
mutants and novel antigenic proteins to select for cells that either have dampened 
antigen presentation or eliminate highly antigenic variants to produce cellular 
populations capable of escape.  
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Evidence has steadily accumulated to suggest that measures of immune activity can be 
associated with prognosis and that signaling through specific pathways in cancer cells 
can result in alterations in external immune function, and that the presence of distinct 
antigenic and mutational signatures can be indicative not only of prognosis but of 
response to immunotherapies that enable the immune system to counter tumours that 
have, through prior immunoediting, evolved to convert an anti-tumour immune 
microenvironment to a pro-tumour immune microenvironment (Snyder, Makarov et al. 
2014, Rizvi, Hellmann et al. 2015, Hugo, Zaretsky et al. 2016).  
Multiple methods have been recently developed to permit the in-silico deconvolution of 
complex cellular mixtures and to estimate tumour purity, be they reference-free 
methods (Houseman, Molitor et al. 2014) or reference-based methods (Koestler, 
Christensen et al. 2013, Jaffe and Irizarry 2014). Methylation data particularly have been 
demonstrated to be amenable to deconvolution of complex tissue mixtures, as 
demonstrated in the deconvolution of blood.  
In this chapter, I document the development of a cellular deconvolution approach on 
bulk tumours using methylation data and combine it with the results of the previous 
chapters and molecular classification to delineate the role of the immune system in the 
context of HPV-driven cancers, including in light of the aggressiveness based 
classification previously derived.  
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Methylation modelling yields an accurate cellular deconvolution 
approach based on Support Vector Regression.  
A variety of methods have been developed to deconvolute complex cellular mixtures 
into component cellular fractions using methylation data, mostly in the context of blood. 
Support Vector Regression has previously been used with expression data and bulk 
tumour transcriptomes to break down the haematopoietic fraction of cells into 
component populations (Newman, Liu et al. 2015). In order to deconvolute bulk 
methylomes into tumour, stroma and immune cell subtype-associated components, I 
assembled and curated a collection of methylomes consisting of HNSC and CESC cell 
lines to serve as the tumour reference, fibroblast samples to serve as stromal 
representations, and eight distinct cell types and performed feature selection to identify 
a total of 510 probes to discriminate between these cell types using support vector 
regression (referred to from this point onwards as MethylCIBERSORT) (Figure 41A).  
The accuracy of the estimates was gauged by comparison to previously published 
ABSOLUTE-estimates of tumour-purity available for 466 HNSC. ABSOLUTE (Carter, 
Cibulskis et al. 2012) uses mutation/copy-number data to jointly optimize the best 
model for purity, ploidy and observed variant allele frequencies and has been 
demonstrated to be highly accurate in previously published work by comparisons with 
flow-cytometry analysis. A high magnitude of correlation was revealed between 
MethylCIBERSORT estimates and ABSOLUTE purity estimates (R = 0.79, p < 2.2e-16, 
Spearman’s Rank Correlation), confirming the utility of the method in deconvoluting 
fractions within bulk tumour samples (Figure 41B).  
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Figure 41: A) Heatmap showing cell-type specific markers used for deconvolution, rows are 
features and columns are samples, B) Comparisons for estimated cancer cell content 
between ABSOLUTE (Reference Gold Standard) and other methods. Y-axis = ABSOLUTE 
cancer cell content, X- asix, method specific estimates. R= Spearman’s Rho. 
MethylCIBERSORT outperforms previously published methods. Data for histopathological 
estimates, ESTIMATE estimates and LUMP for HNSC samples retrieved from (Aran, Sirota et 
al. 2016). 
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Figure 42: MethylCIBERSORT estimates are significantly correlated with expression of 
marker genes. Y Axis = Transcript counts (log2 cpm), X axis = MethylCIBERSORT estimate. 
*** = BHFDR < 0.01, R = Spearman's Rho. Estimates from 466 HNSC coloured by Anatomic 
subsite and HPV status to permit comparison with transcript-wise distributions visualised in 
Chapter 1.  
 
 
 
165 
 
Notably, MethylCIBERSORT outperforms previously published methods of estimating 
tumour purity such as LUMP (Aran, Sirota et al. 2015), which also uses methylation data 
(R=0.51 with ABSOLUTE, p < 2.2e-16) and ESTIMATE (Yoshihara, Shahmoradgoli et al. 
2013)(R= 0.54, p < 2.2e-16) (Figure 43B).   Additional validation was carried out by 
estimating correlations between transcription of key marker genes (CD19 for B Cells, 
FOXP3 for Tregs, CD8A/CD8B for CD8+ lymphocytes) and the estimated immune cell 
fractions. In every case, significant correlations (Range – 0.36 to 0.77) were observed 
between transcript levels and estimated infiltrate. Taken together, these findings 
establish MethylCIBERSORT as a useful approach for probing immune cell content in 
admixed tumours and facilitate deep deconvolution of tumour cell components, as 
opposed to simple division into tumour, immune and stromal components.  
Variability in Immune Cell Content is associated with Cervical 
Cancer Aggressiveness. 
In Chapter 7, I identified patterns that divided cervical cancers into two subgroups with 
distinct prognoses. The SVM classifier developed using early stage tumours was then 
applied to the entirety of the 844 methylomes assembled to serve as the discovery set in 
Chapter 5. Cell fraction estimates were compared for all HPV+ CESC subsequently and 
significantly lower fractions of Natural Killer cells (CD56+, Median FC = 0.59), monocytes 
(FC = 0.72) and Granulocytes (Median FC= 0.59), and elevated levels of CD8+ 
lymphocytes (Median FC = 1.54) (all at FDR < 0.02, Wilcoxon’s Rank Sum Test) were 
identified in HPV16-like tumours relative to HPV45-like tumours (Figure 43).  
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Figure 43: Estimated Immune Cell Fractions for different Immune Cell Types vary with 
Cervical Cancer Aggressiveness Cluster (All TCGA CESCs). *= FDR < 0.05, *** = FDR < 0.001. 
FDR computed using BH-correction from Wilcoxon’s Rank Sum Test P-values. Horizontal 
bars represent groupwise medians. X axis = Aggressiveness Cluster. Y axis = Estimated 
fraction for cell type in facet.  Fold Changes defined as fraction in HPV16 relative to HPV45. 
The prognostic utility of high neutrophil : lymphocyte ratios has been previously 
documented in large cohorts of cervical cancers (Lee, Choi et al. 2012, Mizunuma, 
Yokoyama et al. 2015) and Neutrophils are the most abundant subset of Granulocytes. 
Consequently, in this context, infiltrating cell estimates implicate putative mediators of 
link between molecularly-defined profiles and outcomes.  
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NK-cells have previously been implicated as a pro-survival factor in multiple cancers, 
raising questions of why high levels of this cellular subset are a feature of these 
aggressive tumours.  In HPV45+ tumours that served as the reference point for the 
definition of the signatures behind the original class allocation, it is notable that in 
TGFB1 (> 2FC) and TGFB2 (> 7FC) expression are highly upregulated, and TGF-Beta is 
known to induce suppression of NK-cell activity, potentially resolving this conflict 
(Chang, Li et al. 2016).  
Integrative Analysis of Immune Cell Signatures in HPV+ tumours.  
A pairwise correlation analysis was then carried out to examine if there were statistical 
associations between different infiltrating cell types in the 356 HPV+ tumours (CESC and 
HNSC) that were methylation profiled by TCGA. Significant associations were noticed for 
19/36 pairs of infiltrating cell-types (Spearman’s Rank Correlation, FDR < 0.01) (Figure 
44). This suggested that distinct subsets of infiltrating cells could potentially be 
associated with diverse biology in these tumours. In order to fully integrate cellular 
abundance estimates with immune function, I carried out joint-clustering of these 
estimates with lymphocyte effector markers using a combination of PAM clustering and 
a Random Forest dissimilarity matrix. This identified two major clusters, which displayed 
significant differences in the distributions of abundance estimates for 8/9 cell types (FDR 
< 0.05, Wilcoxon’s Rank Sum Test). One group (C1, aka Immunoreactive) was 
characterised by high levels of CD4+ Tregs, CD8+ Lymphocytes, CD19+ lymphocytes and 
NK-cells whereas the other (C2, Immunodepleted) was characterised by high levels of 
fibroblasts, Granulocytes and CD4+ non-Treg cells (Figure 45).   
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Figure 44: Pairwise correlation matrix of infiltrating cell type abundances estimated using 
MethylCIBERSORT in 356 HPV+ HNSC and CESC highlights multiple significant associations. 
Numbers in cells represent Spearman’s Rho. Back boxes at bottom corners indicate 
statistically significant correlations at FDR < 0.01 
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Figure 45: Distributions of Immune cells vary markedly by Immune Cluster. Y axis = 
estimated fraction per sample. X axis = Cluster. Crossbars represent group medians and 
colours represent overlaps with HPV Aggressiveness Classes. Fold changes calculated as 
medians of Cluster1/Cluster2. * = FDR < 0.05, *** = FDR < 0.001 
 
In order to understand the biological significance of these two distinct patterns of 
infiltration and evaluate if they are associated with distinct patterns of molecular 
alterations, I performed comprehensive analyses of differences in gene expression, 
protein abundance / activity, and DNA methylation patterns with a functional impact on 
shaping gene expression between the two immune clusters. Limma-trend analysis of 
expression data identified 1176 DEGs (FDR < 0.01, > 2FC) between the two clusters 
(Figure 46). 
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Figure 46: Heatmap of 1176 genes differentially expressed between the two Immune 
Clusters (FDR < 0.01, 2FC). Rows represent genes, intensities represent expression Z-scores 
and columns represent samples.  
 
Pathway analyses were highly reflective of differential immune activity, with the top 5 
Canonical Pathways including Crosstalk between Dendritic Cells and NK Cells, T-Cell 
Differentiation, Altered T-Cell and B-Cell signaling in Rheumatoid Arthritis, Natural Killer 
Cell Signalling, ICOS-ICOSL signaling in Helper T-cells and Allograft Rejection Signalling 
(All at BH FDR < 0.01).  
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Diseases and functions ontology analysis again identified decreased leukocyte and 
lymphocyte migration and activation in Immunodepleted samples and identified 
elevated activity linked of the gene set titled “Infection of Virus” in this cluster. 
Reassuringly, CD8A, the Treg-markers TIGIT and FOXP3, the NK-cell marker NKG7 and 
CD19 were all significantly underexpressed in the Immunodepleted cluster as expected 
from analysis of cluster-wise cellular estimates.  
Upstream regulatory analysis identified differential regulation of multiple key Interferon-
response transcription factors. IRF1, IRF3, IRF5 and IRF7 were inhibited in this cluster 
while IRF4 was activated.   HPV16 E7 has been shown to directly bind to IRF1 and recruit 
HDAC to IRF downstream genes to inactivate transcription (Park, Kim et al. 2000), and 
HPV16 E6 has been shown to interact and block the activity of IRF3 (Ronco, Karpova et 
al. 1998), making these inferences consistent with HPV biology.  
In addition to interferon response genes, several pattern recognition receptors –  TLR7, 
TLR8, and TLR10 are strongly upregulated in Immunoreactive tumours. TLR7 and TLR8 
specifically have been shown to be associated with Langerhans Cells (Fahey, Raff et al. 
2009), suggesting that some of the aforementioned expression changes may indeed be 
due to changes in the microenvironment. Other upstream regulators systematically 
dysregulated include the products of NFkB2 and RELA, FOS, EHF, SMARCA4, EZH2 and 
SPI1 (activated in Immunoreactive tumours) and those of ESR1, ID2 and MSC (activated 
in Immunodepleted tumours). 
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Figure 47: Heatmaps of cfMVP Beta-values (left) and expression of cfMVP-associated genes 
(right). Rows represent features and columns represent samples. Annotation ribbons 
represent Immune Cluster, Aggressiveness Class and Anatomic site respectively. See text for 
definition of cfMVPs and DEGs.  
 
DNA methylation analysis was also carried out to estimate if underlying DNA 
methylation changes could be driving disparities between the two clusters and 190 
cfMVPs (median deltaBeta = 0.15, FDR < 0.01), mapping to 109 DEGs, were identified to 
be differentially methylated between the two Immune clusters (Figure 47). Upstream 
regulatory analysis inferred inhibition of IRF7 in Immunodepleted tumours, with CCL5, 
IFIT1, STAT1 and TRAF1 all epigenetically silenced.  
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The suppression of STAT1 expression through HPV E6 and E7 has been demonstrated to 
be integral for genome amplification and plasmid maintenance of HPV16 in keratinocyte 
models (Hong, Mehta et al. 2011) and further reinforces the theme of HPV biology 
shaping molecular profiles that has been established in this thesis. STAT1 in mice has 
been shown to play a potent role in increasing antigen presentation when cancer-cell 
intrinsic and has been associated with the full activation of infiltrating adaptive immune 
cells when extrinsic (Meissl, Macho-Maschler et al. 2015), and may be an example of 
epigenetic events playing a role in immune evasion. These epigenetic events, along with 
those regulating the expression of checkpoints like HAVCR2 (Anderson 2014) , cytosolic 
DNA sensors like AIM2 (Man, Karki et al. 2016), and components of MHC class II 
molecules such as HLA-DPA and HLA-DPB may be targets for potentiating 
immunotherapeutic interventions through the pharmacological modulation of DNA 
methylation.  
Analysis of RPPA (Reverse Phase Protein Array) data identified differential antibody 
binding for 11 proteins between the two immune clusters (FDR < 0.01).  IGFBP2, 
Tafazzin, Fibronectin and AMPK were upregulated in the Immunodepleted group and Lck 
(lymphocyte specific, (Moogk, Zhong et al. 2016)),Bim, PREX1,STAT5-alpha and cleaved 
Caspase 7 were upregulated in the Immunoenriched group. The limited coverage of the 
RPPA platform (192 antibodies) and the small number of samples (n = 162, all CESC) 
represented render functional inferences challenging.   A key limitation of these analyses 
is it is difficult to disentangle the transcriptional, epigenomic and proteomic 
contributions of tumour cells from those of immune cells. Molecular profiling of 
dissociated tumour and immune cells is an experimental step that will facilitate this.  
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Survival analyses of Immune Clusters suggests they comprise 
prognostically equivalent states of the Immune microenvironment. 
Finally, survival analyses were carried out to estimate the contributions of immune 
clusters to survival using Cox models containing Immune cluster, age, and stage across 
the cohort of HPV+ tumours for which clinical data were available (n = 337), separately 
for the Head and Neck and the Cervix.  
The immune signature did not display significant associations in either setting (HR = 
1.37597, p=0.22 for CESC, HR = 2.3, p = 0.34). This finding suggests that the two distinct 
immune environments do not make significantly large contributions to survival 
differences once other clinical factors have been taken into consideration in the setting 
of traditional therapeutic modalities.  
This was surprising given the prognostic value of the Immune-panel cluster derived in 
Chapter 3, which strongly suggested that HPV-driven cancers could be subject to 
immune activity in prognostically-relevant ways. This led me to evaluate alternate Cox 
models regressing measures of cellular abundance along with clinical covariates using 
two distinct stratification approaches. 
 One involved estimation of coefficients per percent increase in infiltrating cell 
abundance while including all available infiltrating cell types with age and stage as 
clinical covariates, while the other involved stratifying into quartiles and evaluating the 
prognostic difference between the top and bottom quartiles with the aforementioned 
covariates (but only evaluating one cell type at a time).   
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Cell Type 
CESC 
Key – HR ( P-value ) 
HNSC 
Key – HR ( P-value ) 
CD14 1.11 ( p = 0.024 ) 0.65   ( p = 0.10 ) 
CD19 0.90 ( p = 0.024 ) 1.001 ( p = 0.98 ) 
CD8 1.05 ( p = 0.043 ) 2.04   (p = 0.034) 
Granulocytes 1.04 ( p = 0.1 ) 3.88   ( p = 0.01 ) 
CD4+ Treg 0.95 ( p = 0.28 ) 1.75    ( p = 0.032 ) 
CD56 (NK Cells) 0.99  ( p = 0.99 ) 1.14     (  p = 0.47 ) 
Eosinophils 1.09  ( p = 0.16 ) 4.14     ( p = 0.029 ) 
Fibroblasts 1.04  ( p = 0.069 ) 0.96     ( p = 0.82 ) 
CD4+ Helper Cells 1.04  ( p = 0.04 ) 0.19     ( p = 0.03 ) 
Table 7: Table of Cox regression coefficients and P values from additive model with all 
infiltrating cell types with age and stage as covariates. Significant associations in blue text. 
Hazard Ratios are per percent increase in estimated fraction of the corresponding cell types. 
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Across the two anatomical subsites, different cell types were associated with different 
Hazard ratios after controlling for other cell types and some cell types were significant 
specifically in one anatomic site but not the other (Table 7). It is however difficult to 
make direct comparisons across anatomic sites. In models that evaluated differences 
between top and bottom quartiles, there were no significant associations found within 
HNSC, while CD4+ Tregs (HR = 0.45, p = 0.03 ) and CD19 (HR = 0.37 , p = 0.01) were 
found to be significant predictors in CESC. A comparative evaluation of the different 
survival modelling strategies is beyond the scope of this thesis.  
Chapter Conclusions  
In this chapter, I developed and characterized a method for estimating the cellular 
abundances of different infiltrating cell types in tumours using methylation data and 
demonstrated that accurate estimates and inferences can be drawn using the 
MethylCIBERSORT approach. As more methylation profiles are generated from cancer 
cell lines and immune subtypes with different tissues of origin, it will be possible to 
perform effective cellular deconvolution at higher resolution across a broad spectrum of 
cancer types. This should facilitate investigation of the immunological repertoire of 
cancers on a pan-tissue basis.  
Differences in infiltrating cell fractions are associated with the Aggressiveness 
Classes/Clusters of Cervical Cancer defined in previous chapters on the basis of HPV-type 
associated molecular variation and may explain some of the prognostic differences 
between these classes.  
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An integrative clustering approach identified two distinct patterns of immune infiltration 
and activity with epigenetic, transcriptomic and proteomic correlates that may both 
serve as alternate mechanisms of immune evasion that prevent tumour destruction. 
Some of these alterations, especially epigenetic ones, could be amenable to therapeutic 
targeting to potentiate anti-tumour immune responses.  
Finally, novel associations were uncovered between abundances of different cell types in 
tumours defined by anatomic site, serving as a starting point for generating hypotheses 
into immune dysregulation in these cancers.  Unanswered questions at this point include 
whether episomal and integrant HPV-driven tumours demonstrate alternate 
mechanisms for immune evasion, and the role of mutational repertoire and other 
genomic alterations in determining immune cluster membership and antitumour 
immunity.  
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Discussion 
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Pan-tissue transcriptional similarities unify HPV driven cancers.  
At the outset of this thesis, the evidence supporting the existence of HPV-specific, 
tissue-independent molecular profiles was sparse and fragmented. Integrating multiple 
collections of HPV transcriptional profiles led to the development of the most 
comprehensive transcriptional signature for HPV-driven carcinogenesis to date, which 
appeared to be generated by a combination of HPV oncoprotein expression and 
additional cellular changes in this context. 
While some of the evidence showing this in transformed keratinocytes and transformed 
Mesenchymal Stem Cells was limited by the lack of HPV- tumour controls, the original 
process for deriving the metasignature and the validation of the metasignature using 
machine learning approaches in the TCGA cohort (n=566 samples, 68 HPV+) established 
the specificity of this transcriptional signature to tumours actively expressing HPV 
oncoproteins, bypassing the caveats associated with analyses limited to HPV DNA+ 
tumours that may not be actively transcribing HPV.   
Many of these changes, upon functional annotation, reflected classically established 
facts in the biology of HPV and point towards HPV as the key player in shaping the 
evolution of these patterns.  
Examination of these expression patterns across multiple cancer types revealed the 
magnitude and the involvement of multiple HPV-associated transcriptional changes of a 
large subset was unique to HPV-driven tumours.  
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Successful identification of a driver role for HPV in non-Oropharyngeal HNSCs uncovers 
a role for immune response in mediating outcomes.  
There have been outstanding questions in the field regarding the contribution of HPV to 
the establishment of tumours in HNSCs that lie outside the Oropharynx, where HPV DNA 
is found at low frequencies compared to OPSCCs which display high aetiological burdens 
for HPV, as well as to prognosis, which is excellent in HPV+ OPSCC but is vastly more 
ambiguous outside the Oropharynx.  
Leveraging on the ability to identify active HPV-transcription, and applying classifiers 
trained on pan-tissue signatures of HPV-induced transformation derived earlier in the 
thesis leads to the conclusion HPV plays a driver role in non-OPSCCs that display active 
HPV transcription but show outcomes more comparable to HPV- tumours because of 
differences in immune infiltration, which corresponds to differential transcription of CD8 
effector molecules and is marked by a distinct expression pattern of immune checkpoint 
transcripts which overall split HPV+ HNSCs into groups with different outcomes . 
 These findings suggest a pathway towards patient stratification, where molecular 
markers are used to classify tumours by HPV-status initially, followed by an evaluation of 
TIL infiltration levels or immune checkpoint expression, in order to select patients for 
treatment with immunotherapy, which I hypothesize will demonstrate efficacy especially 
in TIL-High and Checkpoint-High tumours.  
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APOBEC-mediated mutagenesis links transcriptional and genomic evolution of HPV+ 
tumours.  
It has long been known that additional genomic events are required to convert cells that 
express E6 and E7 constitutively to fully malignant cells, but it was unclear if HPV played 
an active role in driving these evolutionary processes or whether the acquisition of 
additional hits was a statistically independent process. While E7 induced chromosomal 
instability and the abrogation of p53 permitting evasion of cell-cycle arrest have been 
previously documented, it has been unclear what role HPV may play in shaping the 
evolution of single nucleotide variants in these tumours.  
The derivation of the pan-tissue transcriptional signature for HPV+ tumours highlighted 
upregulation of genes reflective of replication fork stalling as well as the cytosine 
deaminase APOBEC3B as a feature of these tumours.  
Leveraging on prior work on APOBEC as a mutator in human cancers, I tested statistical 
measures for measuring APOBEC-mediated mutagenesis in tumour exomes, and showed 
that these patterns contributed to a large fraction of mutations in HPV+ tumours relative 
to HPV- tumours while not being part of a general mutator phenotype in viral cancers, 
both when assessed exome-wide and in mutations likely to be drivers of malignancy.  
The serendipitous discovery of PIK3CA as a gene recurrently mutated by APOBEC, albeit 
in a hotspot specific manner lead to the identification of likely activity of APOBEC 
through substrate nucleotide sequences as the mutagenic process responsible for the 
origins of these mutations.  
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This relationship between a preference for helical hotspot mutations in PIK3CA and 
levels of APOBEC-activity is preserved across cancer types, and given what appears to be 
similar selective impact conferred by the two different PIK3CA hotspot mutations, 
establishes mutational processes as one of the key determinants of what mutations may 
arise in a tumour type, which will be followed by natural selection acting on those 
variants. To summarize, the transcriptional signature mediates the involvement of HPV 
in the genomic evolution of these tumours in previously undiscovered ways.   
A distinct, yet complex, set of epigenetic changes defines HPV-driven tumourigenesis.  
The fragmented nature of understanding regarding HPV-driven tumourigenesis that was 
true of transcriptome studies was also true of the methylome. Using the largest 
assembled set of methylomes from HPV+ tumours and corresponding normal and HPV- 
controls to date, I showed the existence of conserved methylation profiles and identified 
that only a subset of these displayed association with gene expression in canonically 
defined ways.  
On a global scale, HPV+ tumours display a signature of genome-wide hypermethylation 
relative to HPV- tumours/normal tissues, which has been subject to speculation 
following prior studies. Some prominent HPV-induced transcriptional changes, such as 
the expression of the meiotic cohesin component SYCP2 appear to be mediated by 
hypomethylation events at a CpG Island DMR that is methylated in HPV- tissue and 
normal cells. 
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 While the contributions of methylation to shaping transcription in these tumours are 
fragmented and methylation by itself does not dysregulate entire pathways, some of the 
genes silenced by methylation, such as PITX2, have been shown to have potent anti-HPV 
functions, conferring a putative driver status for this epigenetic event.  
In addition to traditionally well-known mechanisms of action for DNA methylation, my 
analyses uncovered a role for enhancer-element methylation events as transcriptional 
regulators in these tumours. While the 450k array is limited in terms of coverage of CpG 
sites at putative enhancers, decreases in costs of large-scale bisulfite sequencing and 
emerging array-based platforms that also include FANTOM5 documented enhancers 
(Moran, Arribas et al. 2016) should facilitate investigations into what long-range 
regulatory changes influence the transcriptional landscape and the evolution of HPV+ 
tumours.  
DNA demethylating agents have recently gained attention for clinical use at low doses, 
with novel mechanisms currently being reported as being responsible for durable 
responses (Roulois, Loo Yau et al. 2015). Interfering with DNA methylation in HPV-driven 
tumours, particularly in context of the global hypermethylation that defines these 
tumours, should exert pleiotropic effects on tumour biology. Possible bases for the 
activity of DNA methylation inhibitors in this disease setting include interfering with 
E6/E7 function and stimulating anti-tumour immune responses.  
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Epigenomic and Transcriptional Analyses of Cell-of-origin signatures has implications 
for putative pathways to malignancies at different anatomical sites.  
The discovery of variations in KRT7 methylation and expression amongst different 
subgroups of HPV-driven tumours raised intriguing questions about the origin and 
evolution of HPV-driven cancers. The identification of two distinct clusters of expression 
of a gene set attributed to squamocolumnar junction cells is consistent with multiple 
models by which these tumours originate; these differences could either result from 
different HPV types infecting and transforming different cell types, with transcriptional 
heterogeneity a consequence of transcriptional variation by cell type, or from HPV and 
the subsequent genomic milieu in transformed cells interacting to perturb the 
expression of these genes to different extents in different HPV-driven cancers.  
Unifying molecular profiles may improve HPV-status detection. 
In Chapter 5, the datasets used for methylation analysis used a wide range of methods 
to call HPV-types. Traditional DNA-based methods may have issues with false-positives 
picked up from passenger infections or inactivated viral genome remnants, and indirect 
markers such as p16 staining are known to be poor indicators of HPV-status outside the 
Oropharynx insofar HNSC is concerned (Lassen, Primdahl et al. 2014). Approaches to call 
HPV-status based on RNA-seq to date are often dataset specific (Ojesina, Lichtenstein et 
al. 2014, 2015) (TCGA 2015) in terms of using bimodal distributions to call samples 
positive and there is no gold-standard for estimating if a tumour is HPV+ based on RNA-
seq.  
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Another possibility is that there may be bystander HPV-infections or issues with 
contamination that compromise detection using HPV-transcription. I propose that the 
pan-tissue HPV-expression and methylation signatures established in this thesis may be 
a starting point for robust biomarkers to identify tumours that are truly driven by HPV.  
Molecular heterogeneity links taxonomic variation in HPV to clinical behaviour in 
Cervical Cancers.  
In Head and Neck Cancers, the vast majority of HPV+ tumours are caused by HPV16, 
with minor contributions from other types and almost never HPV types such as HPV45 
and HPV18 that are vastly more common in CESC. This meant that HPV16 was likely to 
introduce a type specific bias when carrying out the initial analyses that defined pan-
tissue signatures for HPV-driven transformation. Given prior evidence hinting at 
molecular and clinical differences by HPV-type, and what appeared to be different 
tissue-tropism amongst HPV types, I was led to explore the relationship between 
taxonomic groups of HPV and molecular and clinical differences.  
Clinical data analysis suggested that the most pronounced clinical differences emerged 
when comparing HPV16-driven tumours with HPV45-driven tumours. Computational 
analyses of expression and methylation data from these led to the identification of 
large-scale differences in gene-expression and expression-associated DNA methylation 
patterns. Pathway analysis of the expression signature suggested these tumours 
displayed a profile for aggressive behaviour, even when tumours were pathologically 
regarded as Stage I or Stage II.  
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Using Random Forests for joint-clustering of data types, I showed these patterns 
clustered tumours into HPV45-like and HPV16-like subgroups with markedly different 
outcomes and defined a classifier for application in patient stratification. These 
aggressiveness-associated clusters also show strong overlaps with cell-types defined by 
cell-of-origin signature gene expression.  
The analyses in this chapter suggest that prior analyses that have treated HPV driven 
cancers as a monolith have not recognised the existence of these functionally important 
differences. This also has bearings on interpretation of gene-expression changes that are 
found in pan-tissue signatures as “HPV-specific” phenomena instead of “HPV-subtype 
specific” phenomena. For instance, HPV45+ tumours display high levels of CCND1 
expression relative to HPV16+ tumours and counter the notion that CCND1 activation 
mediates cell death if CDKN2A expression is silenced across all HPV-driven tumours 
instead of just HPV16-driven tumours (McLaughlin-Drubin, Park et al. 2013).  
It is particularly striking that clustering using the HPV45 signature has prognostic value 
across the entirety of the cohort, independent of HPV type, and has prognostic value in 
cervical cancers caused by HPV16 and HPV18, making it possible to apply these patterns 
for patient stratification across all cervical cancers when samples are initially biopsied. 
The fact that these Aggressiveness Classes cross lines of cellular origin and histology 
identifies fundamental truths about the behaviour of these tumours. There is an 
opportunity for future work to build upon these findings to further understand the 
determinants of these transcriptional and epigenetic profiles, be they viral or cellular, 
and to test this classification scheme for patient management.  
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Analysis of Immune Microenvironment across HPV+ cancers identifies two broad 
immune profiles.  
Finally, I developed regression based methods for estimating the immune 
microenvironment of HPV+ tumours, and found that HPV45-like tumours were marked 
by depleted levels of CD8+ TILs and high levels of infiltrating Natural Killer and 
Granulocytes, consistent with prior evidence for patterns of immune-cells and prognosis, 
which is also consistent with high levels of expression of CD276, a checkpoint-regulator, 
in these tumours, suggesting a potential target for immunotherapy (Pardoll 2012).  
Joint clustering based on immune effectors and infiltration estimates identified an 
immunoreactive and an immunodepleted group within HPV+ tumours, with the former 
defined by overexpression of multiple mediators of immune cell signalling and function. 
The presence of high levels of immune infiltrates and checkpoint activity within these 
tumours indicates potential for the use of immunotherapies in their treatment. A 
considerable fraction of HPV45-like tumours also display an immunoenriched subtype 
characterised by high levels of CD8+ lymphocytes and Tregs, identifying a subgroup that 
may benefit from immune checkpoint modulation.  
The MethylCIBERSORT approach, developed for deep deconvolution of immune cell 
subsets using methylation data, will facilitate more detailed future investigations into 
the interplay between molecular alterations and immune cell distributions across cancer 
types. In the future, higher resolution DNA methylation assays should permit greater 
discrimination of a larger number of cell types, and refine the profiles used to estimate 
cellular composition by using immune cells obtained through the direct dissociation of 
tumour-associated immune cells and other infiltrating cells.  
188 
 
To summarise, these findings implicate marked differences in the means of 
immunoevasion amongst HPV+ tumours and lay the foundations for further work into 
manipulating these pathways for therapeutic purposes.  
Preservation of molecular profiles has implications for therapy.  
Results from Chapter 5 demonstrate that epigenetic profiles and the expression profiles 
of DNA-methylation associated genes are preserved across the tumour cohort, including 
genes that are part of the metasignature and those that are putative HPV-associated 
drivers. This implies that HPV plays a continual role in maintaining the viability of these 
tumours, which has been confirmed by others in cell-line studies involving the 
knockdown of E6/E7 (Rampias, Sasaki et al. 2009, Chang, Kuo et al. 2010).  
This dependence on HPV allows for the development of customised T-cell therapies to 
target E6/E7 antigen-displaying cells for immune destruction, and small-scale trials have 
already reported some successes using these approaches (Stevanovic, Draper et al. 
2015) . The presence of HPV, and continued expression thereof, in every cell (NB – clonal 
neoantigens have been proposed to be associated with more potent anti-tumour 
immune activity (McGranahan, Furness et al. 2016)), in combination with general 
immunomodulatory strategies to convert the immune microenvironment of HPV+ 
tumours into one that is amenable to tumour rejection is a feasible pathway towards 
cures. One outstanding question that has not been addressed in the thesis, however, is 
whether metastatic tumours may display vastly different molecular profiles having 
undergone, in the course of tumour evolution, alterations that subvert the signatures 
seen in primary tumours. 
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Final Synthesis  
Finally, I wish to integrate the aforementioned findings into a unified model that links  
origin, molecular profiles, and outcomes in HPV+ tumours, and raises questions for 
further research. Fundamentally, I propose that different high-risk HPV-types show 
differential affinity for transforming two different cell types, one involving homologous 
populations to the squamocolumnar junction cells of the cervix, and one a different 
population for which HPV16 shows greater affinity than other cell types.  
This is consistent with the varying tropism for different HPV types to different regions. 
HPV18, for instance, is restricted to the anus and the uterine cervix, both of which show 
junction-cell populations, whereas in the penis and head and neck regions, HPV18 and 
HPV45 are seldom seen.  
Despite differences in the cell-of-origin for these tumours, the activity of HPV-
oncoproteins can induce a common set of transcriptional, epigenetic and proteomic 
changes. These can have consequences including genomic instability and replication fork 
stalling which potentiate the off-target activity of APOBEC3. APOBEC3-mediated 
mutagenesis then becomes the primary mechanism through which genomic disruption 
occurs on the pathway to full-blown malignancy.  
Unified DNA methylation patterns may be associated with candidate driver epigenetic 
changes that indicate epigenetic therapy may exert pleiotropic effects that ultimately 
subvert HPV-oncoprotein function and HPV-driven cancer cells to collapse.  
190 
 
Despite these common changes, either through the activity of HPV-oncoproteins 
themselves, or the underlying transcriptional and epigenomic architectures of the cell-
of-origin, additional heterogeneity is induced. Some of these involve marked changes in 
pathways associated with metastatic behaviour and a pro-inflammatory 
microenvironment, that translates to abysmal clinical outlook within a subset of 
tumours. Finally, the immune microenvironment appears to be a key selective pressure 
shaping the evolution of these tumours, and two distinct patterns of immune infiltration 
and activity, with associated molecular correlates, are evident.  
In toto, the work in this thesis serves to help identify if a tumour is HPV-driven using 
transcription/DNA-methylation markers, links patterns that unify HPV-driven cancers 
across tissues to mutagenesis and transformation, offering potential scope for 
prevention, and then identifies tumours likely to have diverse cellular origins and clinical 
behaviour. It finally identifies markers of immune activity that may be employed to 
judge who will benefit from immunotherapies, especially if they display molecular 
features of the aggressive subtype, in the process confirming each of the three core 
hypotheses laid out at the outset.  
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A1. List of IPA canonical pathways for the HPV-associated gene expression 
metasignature. 
Ingenuity Canonical Pathways  -log(B-H p-
value) 
Ratio z-score 
Cell Cycle Control of 
Chromosomal Replication 
1.54E+01 3.42E-01 NaN 
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 
9.23E+00 2.04E-01 -2.121 
Mitotic Roles of Polo-Like Kinase 5.55E+00 1.27E-01 1.633 
Cyclins and Cell Cycle Regulation 4.98E+00 1.04E-01 0.378 
GADD45 Signaling 4.84E+00 2.63E-01 NaN 
Mismatch Repair in Eukaryotes 3.62E+00 2.50E-01 NaN 
DNA damage-induced 14-3-3Ïƒ 
Signaling 
3.37E+00 2.11E-01 NaN 
p53 Signaling 3.06E+00 6.31E-02 -0.447 
Estrogen-mediated S-phase Entry 3.05E+00 1.67E-01 1 
Granulocyte Adhesion and 
Diapedesis 
2.90E+00 4.85E-02 NaN 
Cell Cycle: G1/S Checkpoint 
Regulation 
2.53E+00 7.94E-02 1 
Role of BRCA1 in DNA Damage 
Response 
2.14E+00 6.41E-02 NaN 
ATM Signaling 2.14E+00 6.33E-02 -0.447 
Agranulocyte Adhesion and 
Diapedesis 
2.08E+00 4.00E-02 NaN 
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dTMP De Novo Biosynthesis 2.05E+00 4.00E-01 NaN 
Hereditary Breast Cancer 
Signaling 
1.91E+00 4.32E-02 NaN 
Role of CHK Proteins in Cell Cycle 
Checkpoint Control 
1.90E+00 7.27E-02 NaN 
BER pathway 1.33E+00 1.67E-01 NaN 
Small Cell Lung Cancer Signaling 1.30E+00 4.76E-02 NaN 
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A2: Upstream Regulatory Analysis of HPV-associated metasignature.  
Upstream 
Regulator 
Exp Fold 
Change 
Molecule Type Predicted 
Activation 
State 
Activation 
z-score 
Flags p-value of 
overlap 
NUPR1   transcription regulator Inhibited -3.638   5.24E-08 
CDKN2A 19.638 transcription regulator Inhibited -2.205 bias 3.24E-05 
ATF3   transcription regulator Inhibited -2   1.45E-05 
E2F6   transcription regulator Inhibited -2.646 bias 2.64E-12 
KDM5B   transcription regulator Inhibited -3.966 bias 6.91E-17 
TP53   transcription regulator Inhibited -5.45   1.18E-28 
CREB1   transcription regulator Activated 2.646 bias 1.03E-08 
FOXM1 2.439 transcription regulator Activated 3.618 bias 9.43E-26 
FOXO1   transcription regulator Activated 3.688 bias 3.99E-17 
E2F3   transcription regulator Activated 2.53   4.97E-09 
MITF   transcription regulator Activated 3.873 bias 1.12E-16 
TAL1   transcription regulator Activated 2.496   3.38E-10 
RARA   ligand-dependent nuclear receptor Activated 3   1.62E-05 
 
<continued on the next page> 
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A3: Analysis Workflows  
These flowcharts represent the bulk of the analyses that involved multiple datasets in 
generating the results found in Chapters 3, 5,6 and 7.  
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Appendix A4 : Clinical variables in the TCGA HPV+ HNSC cohort and survival analysis 
coefficients from Cox regression. Table reproduced from (Chakravarthy, Henderson et al. 
2016) 
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Appendix A5: K-M curves of survival by histology between HPV16-like and HPV45-like 
tumours in the Norwegian cohort of cervical cancers. The cohort only included 2 
neuroendocrine cancers and ergo have not been plotted.  
 
